<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/195974</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;195974v3</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;195974</article-id><article-id pub-id-type="other" hwp:sub-type="slug">195974</article-id><article-id pub-id-type="other" hwp:sub-type="tag">195974</article-id><article-version>1.3</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Microbiology" hwp:journal="biorxiv"><subject>Microbiology</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Probing the evolutionary robustness of two repurposed drugs targeting iron uptake in <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title></title-group><author-notes hwp:id="author-notes-1"><corresp id="cor1" hwp:id="corresp-1" hwp:rev-id="xref-corresp-1-1 xref-corresp-1-2"><label>*</label>Corresponding authors: Department of Plant and Microbial Biology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Email: <email hwp:id="email-1">chiara.rezzoagli@uzh.ch</email> (CR), <email hwp:id="email-2">rolf.kuemmerli@uzh.ch</email> (RK). Phone: +41 44 635 48 01.</corresp></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" corresp="yes" hwp:id="contrib-1"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8131-3062</contrib-id><name name-style="western" hwp:sortable="Rezzoagli Chiara"><surname>Rezzoagli</surname><given-names>Chiara</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-1" hwp:rel-id="corresp-1">*</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0002-8131-3062"/></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Wilson David"><surname>Wilson</surname><given-names>David</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Weigert Michael"><surname>Weigert</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Wyder Stefan"><surname>Wyder</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-5"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4084-6679</contrib-id><name name-style="western" hwp:sortable="Kümmerli Rolf"><surname>Kümmerli</surname><given-names>Rolf</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-5" hwp:rel-id="aff-1">1</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-2" hwp:rel-id="corresp-1">*</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0003-4084-6679"/></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4 xref-aff-1-5"><label>1</label><institution hwp:id="institution-1">Department of Plant and Microbial Biology, University of Zurich</institution>, Zurich, <country>Switzerland</country></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2017-10-02T15:24:29-07:00">
    <day>2</day><month>10</month><year>2017</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-08-31T14:45:08-07:00">
    <day>31</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2017-10-02T15:29:45-07:00">
    <day>2</day><month>10</month><year>2017</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-08-31T14:52:47-07:00">
    <day>31</day><month>8</month><year>2018</year>
  </pub-date><elocation-id>195974</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2017-10-02"><day>02</day><month>10</month><year>2017</year></date>
<date date-type="rev-recd" hwp:start="2018-08-31"><day>31</day><month>8</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-08-31"><day>31</day><month>8</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="license-1"><p hwp:id="p-1">This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></p></license></permissions><self-uri xlink:href="195974.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/195974v3.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="195974.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/195974v3/195974v3.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/195974v3/195974v3.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><sec hwp:id="sec-1"><title hwp:id="title-2">Background and objectives</title><p hwp:id="p-2">Treatments that inhibit the expression or functioning of bacterial virulence factors hold great promise to be both effective and exert weaker selection for resistance than conventional antibiotics. However, the evolutionary robustness argument, based on the idea that anti-virulence treatments disarm rather than kill pathogens, is controversial. Here we probe the evolutionary robustness of two repurposed drugs, gallium and flucytosine, targeting the iron-scavenging pyoverdine of the opportunistic human pathogen <italic toggle="yes">Pseudomonas aeruginosa</italic>.</p></sec><sec hwp:id="sec-2"><title hwp:id="title-3">Methodology</title><p hwp:id="p-3">We subjected replicated cultures of bacteria to two concentrations of each drug for 20 consecutive days in human serum as an ex-vivo infection model. We screened evolved populations and clones for resistance phenotypes, including the restoration of growth and pyoverdine production, and the evolution of iron uptake by-passing mechanisms. We whole-genome sequenced evolved clones to identify the genetic basis of resistance.</p></sec><sec hwp:id="sec-3"><title hwp:id="title-4">Results</title><p hwp:id="p-4">We found that mutants resistant against anti-virulence treatments readily arose, but their selective spreading varied between treatments. Flucytosine resistance quickly spread in all populations due to disruptive mutations in <italic toggle="yes">upp</italic>, a gene encoding an enzyme required for flucytosine activation. Conversely, resistance against gallium arose only sporadically, and was based on mutations in transcriptional regulators, upregulating pyocyanin production, a redox-active molecule promoting siderophore-independent iron acquisition. The spread of gallium resistance could be hampered because pyocyanin-mediated iron delivery benefits resistant and susceptible cells alike.</p></sec><sec hwp:id="sec-4"><title hwp:id="title-5">Conclusions and implications</title><p hwp:id="p-5">Our work highlights that anti-virulence treatments are not evolutionarily robust <italic toggle="yes">per se</italic>. Instead, evolutionary robustness is a relative measure, with specific treatments occupying different positions on a continuous scale.</p></sec></abstract><counts><page-count count="42"/></counts><custom-meta-wrap>
    <custom-meta hwp:id="custom-meta-1">
      <meta-name>has-earlier-version</meta-name>
      <meta-value>yes</meta-value>
    </custom-meta>
  </custom-meta-wrap></article-meta></front><body><sec id="s1" hwp:id="sec-5"><title hwp:id="title-6">Introduction</title><p hwp:id="p-6">There is currently much interest in therapeutic approaches that inhibit the expression or functioning of bacterial virulence factors [<xref rid="c1" ref-type="bibr" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>–<xref rid="c8" ref-type="bibr" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref>]. Virulence factors are structures and molecules that allow bacteria to establish and maintain infections [<xref rid="c9" ref-type="bibr" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref>, <xref rid="c10" ref-type="bibr" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref>]. Examples of virulence factors include flagella and pili to adhere to the host tissue, secreted enzymes, tissue-damaging toxins and siderophores to scavenge iron from the host [<xref rid="c11" ref-type="bibr" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref>]. Approaches that target these traits are called anti-virulence treatments. There is great hope that disarming rather than killing pathogens is an efficient and evolutionarily robust way to manage infections [<xref rid="c2" ref-type="bibr" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref>, <xref rid="c12" ref-type="bibr" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref>–<xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref>]. In particular, it is assumed that anti-virulence treatments exert weaker selection for resistance than conventional antibiotics because pathogens are not killed directly. However, empirical evidence for the evolutionary robustness of anti-virulence treatments is controversial with positive and negative reports currently balancing each other out [<xref rid="c16" ref-type="bibr" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref>–<xref rid="c21" ref-type="bibr" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref>].</p><p hwp:id="p-7">The controversy entails both conceptual and practical aspects. On the conceptual level, some define anti-virulence approaches as treatments that specifically target virulence factors without affecting pathogen growth [<xref rid="c2" ref-type="bibr" hwp:id="xref-ref-2-2" hwp:rel-id="ref-2">2</xref>, <xref rid="c22" ref-type="bibr" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">22</xref>], while others argue that it is unlikely that virulence factors do not affect pathogen fitness, and thus simply use the mechanistic part of the definition [<xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref>, <xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-2" hwp:rel-id="ref-15">15</xref>]. On the practical level, there are debates about what exactly a resistance phenotype is [<xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-3" hwp:rel-id="ref-15">15</xref>], as it could include restoration of virulence factor production, growth (if affected), and/or the activation of a bypassing mechanism, restoring the virulence phenotype [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref>]. Moreover, there is a shortage of studies examining resistance evolution under realistic conditions in replicated populations, both at the phenotypic and genetic level.</p><p hwp:id="p-8">Here, we tackle these issues by examining the mechanistic and evolutionary potential of resistance evolution against two repurposed drugs, gallium and flucytosine, which both target the iron-scavenging pyoverdine of the opportunistic human pathogen <italic toggle="yes">Pseudomonas aeruginosa</italic> [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-2" hwp:rel-id="ref-19">19</xref>, <xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref>, <xref rid="c24" ref-type="bibr" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref>]. Pyoverdine is an important virulence factor during acute infections [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-3" hwp:rel-id="ref-19">19</xref>, <xref rid="c25" ref-type="bibr" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">25</xref>–<xref rid="c31" ref-type="bibr" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">31</xref>]. It is required to obtain iron from host proteins, such as transferrin and lactoferrin [<xref rid="c32" ref-type="bibr" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">32</xref>]. Given its importance, it has been proposed that drugs interfering with iron uptake could be effective therapeutics to control infections [<xref rid="c33" ref-type="bibr" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">33</xref>]. Gallium and flucytosine both fulfill this role, albeit through different modes of action. Gallium, a repurposed cancer drug, is an iron-mimic and binds irreversibly to secreted pyoverdine, thereby rendering the molecules useless for iron uptake [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-4" hwp:rel-id="ref-19">19</xref>, <xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-2" hwp:rel-id="ref-23">23</xref>, <xref rid="c31" ref-type="bibr" hwp:id="xref-ref-31-2" hwp:rel-id="ref-31">31</xref>]. Flucytosine, a repurposed anti-fungal drug, enters the bacterium, where it is enzymatically activated to a fluorinated ribonucleotide. This active form inhibits, via a yet unknown mechanism, the expression of the <italic toggle="yes">pvdS</italic> iron starvation sigma factor controlling pyoverdine synthesis [<xref rid="c24" ref-type="bibr" hwp:id="xref-ref-24-2" hwp:rel-id="ref-24">24</xref>, <xref rid="c34" ref-type="bibr" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">34</xref>].</p><p hwp:id="p-9">In a first set of experiments, we examined whether these two drugs affect the growth of <italic toggle="yes">P. aeruginosa</italic> in human blood serum, a medium that has recently been established as an ex-vivo infection model [<xref rid="c35" ref-type="bibr" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">35</xref>]. We hypothesize that gallium and flucytosine are likely to reduce pathogen fitness as they induce iron starvation [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-5" hwp:rel-id="ref-19">19</xref>, <xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-3" hwp:rel-id="ref-23">23</xref>, <xref rid="c36" ref-type="bibr" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">36</xref>, <xref rid="c37" ref-type="bibr" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">37</xref>]. In addition, anti-virulence drugs, like any other drugs, might have deleterious off-target effects affecting growth. Gallium at high dosage, for instance, can penetrate into bacterial cells, where it interferes with redox-active enzymes [<xref rid="c38" ref-type="bibr" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">38</xref>, <xref rid="c39" ref-type="bibr" hwp:id="xref-ref-39-1" hwp:rel-id="ref-39">39</xref>]. Flucytosine, once activated, is known to affect RNA synthesis, which might negatively affect growth [<xref rid="c40" ref-type="bibr" hwp:id="xref-ref-40-1" hwp:rel-id="ref-40">40</xref>].</p><p hwp:id="p-10">In a second experiment, we examined whether mutants, resistant against these two repurposed drugs, evolve and spread through bacterial populations. To this end, we exposed replicated populations of <italic toggle="yes">P. aeruginosa</italic> to two different concentrations of gallium and flucytosine in human serum. Together with a drug-free control treatment, we let the treated populations evolve for 20 consecutive days in eight-fold replication, by transferring a fraction of the evolving cultures to fresh human serum on a daily basis. Following experimental evolution, we screened evolved populations and clones for possible resistance phenotypes, including the restoration of growth, restoration of virulence factor production, and the evolution of a bypassing mechanism for iron uptake [<xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-4" hwp:rel-id="ref-15">15</xref>, <xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-6" hwp:rel-id="ref-19">19</xref>]. Finally, we sequenced the whole genome of evolved clones to uncover the genetic basis of potential resistance mechanisms.</p><p hwp:id="p-11">Resistance evolution requires two processes: the supply of mutations conferring resistance and appropriate selection regimes favoring the spread of these mutants [<xref rid="c41" ref-type="bibr" hwp:id="xref-ref-41-1" hwp:rel-id="ref-41">41</xref>]. With regard to mutation supply, some common resistance mechanisms (e.g. drug degradation, prevention of drug influx and increased drug efflux) are less likely to apply for gallium, which is an ion and acts outside the cell [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-7" hwp:rel-id="ref-19">19</xref>]. Therefore, with fewer possible routes to resistance being available, we predict gallium to show higher evolutionarily robustness than flucytosine. However, as for the spread of mutants, both drugs could be evolutionarily robust because they target a secreted virulence factor, which can be shared as a public good between pathogen individuals (iron-loaded pyoverdine can be taken up by all bacteria with a matching receptor; [<xref rid="c42" ref-type="bibr" hwp:id="xref-ref-42-1" hwp:rel-id="ref-42">42</xref>, <xref rid="c43" ref-type="bibr" hwp:id="xref-ref-43-1" hwp:rel-id="ref-43">43</xref>]). Consequently, if resistance entails the resumption of virulence factor production then resistant mutants should not spread because they bear the cost of resumed virulence factor production, whilst sharing the benefit with everyone else in the population, including the drug-susceptible individuals [<xref rid="c12" ref-type="bibr" hwp:id="xref-ref-12-2" hwp:rel-id="ref-12">12</xref>, <xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref>, <xref rid="c16" ref-type="bibr" hwp:id="xref-ref-16-2" hwp:rel-id="ref-16">16</xref>, <xref rid="c20" ref-type="bibr" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref>]. Conversely, if these drugs have deleterious off-target effects, we predict the evolutionary robustness to decline, and accelerated spread of resistance under drug exposure, as for traditional antibiotics.</p></sec><sec id="s2" hwp:id="sec-6"><title hwp:id="title-7">Methodology</title><sec id="s2a" hwp:id="sec-7"><title hwp:id="title-8">Strains and culturing conditions</title><p hwp:id="p-12">We used the genetically well-characterized <italic toggle="yes">P. aeruginosa</italic> PAO1 wildtype strain for all experiments. For some assays, we further used a set of knockout mutants in the PAO1 background as control strains (see Supplementary Table S1). Overnight cultures were grown in 8 ml Lysogeny broth (LB) in 50-ml Falcon tubes, incubated at 37°C, 200 rpm for 18 hours.</p><p hwp:id="p-13">For all experiments, we washed overnight cultures with 0.8% NaCl solution and adjusted them to OD<sub>600</sub> = 2.5. Bacteria were further diluted to a final starting of OD<sub>600</sub> = 2.5 × 10<sup>−3</sup>. All experiments were carried out in human serum, supplemented with HEPES (50 mM) to buffer the medium at physiological pH. Moreover, to impose a standardized iron limitation across experiments, we added the iron chelator human apo-transferrin (100 μg/ml), which is typically present in blood serum at high concentration, and its co-factor NaHCO<sub>3</sub> (20 mM). We used gallium (GaNO<sub>3</sub>) and flucytosine (5-Fluorocytosine) as anti-bacterials. All chemicals, including human serum, were purchased from Sigma-Aldrich, Switzerland.</p></sec><sec id="s2b" hwp:id="sec-8"><title hwp:id="title-9">Growth and virulence factor inhibition curves</title><p hwp:id="p-14">To assess the extent to which gallium and flucytosine inhibit PAO1 growth and pyoverdine production, we subjected bacterial cultures to a seven-step antibacterial concentration gradient: 0 - 512 µM for GaNO<sub>3</sub> and 0-140 µg/ml for flucytosine. Overnight cultures of bacteria were grown and diluted as described above and inoculated into 200 μl of human serum on 96-well plates. Plates were incubated at 37 °C in a Tecan Infinite M-200 plate reader (Tecan Group Ltd., Switzerland). We tracked growth by measuring OD at 600 nm and pyoverdine-associated natural fluorescence (excitation: 400 nm, emission: 460 nm) every 15 minutes for 24 hours. Plates were shaken for 15 seconds (3 mm orbital displacement) prior to each reading event.</p></sec><sec id="s2c" hwp:id="sec-9"><title hwp:id="title-10">Experimental evolution</title><p hwp:id="p-15">We exposed wildtype cultures of PAO1 to experimental evolution for 20 days under five different selective regimes in eight-fold replication. The five regimes included a no-drug control, and a low and a high concentration treatment for both drugs (gallium: 50 μM and 280 μM; flucytosine: 10 μg/ml and 140 μg/ml). The antibacterial concentrations were inferred from the dose-response curves (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Fig. 1</xref>). To initiate experimental evolution, an overnight culture of PAO1 was grown as described above, and individual wells on a 96-well plate were inoculated with 10 μl of culture (diluted to a final density of 10<sup>6</sup> cells per well) in 190 μl iron-limited human serum. Incubation occurred in the plate reader at 37°C for 23.5 hours, and OD<sub>600</sub> was measured every 15 minutes prior to a brief shaking event. Subsequently, cultures were diluted in 0.8% NaCl and transferred to a new plate containing fresh media. We adjusted the dilution factor proportional to the overall growth per treatment; no-drug control: 2 × 10<sup>−3</sup> (day 1-10) and 4*10<sup>−3</sup> (day 11-20); antibacterial treatments: 10<sup>−3</sup> (day 1-10) and 2 × 10<sup>−3</sup> (day 11-20). Following transfers, we added 100 μl of a 50% glycerol-LB solution to cultures for storage at −80°C.</p><fig id="fig1" position="float" fig-type="figure" orientation="portrait" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2 xref-fig-1-3 xref-fig-1-4 xref-fig-1-5 xref-fig-1-6 xref-fig-1-7"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;195974v3/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1.</label><caption hwp:id="caption-1"><title hwp:id="title-11">Gallium and flucytosine affect both growth and pyoverdine production of <italic toggle="yes">P. aeruginosa</italic> in human serum (HS).</title><p hwp:id="p-16">Both anti-virulence drugs reduce growth of bacterial cultures in a dose-dependent manner (A, B), albeit following different patterns: gallium curbs bacterial growth only at relatively high concentrations (A), whereas flucytosine already reduces growth at low concentrations (B). Both drugs further affect pyoverdine production (C, D). When increasing gallium exposure, bacteria first upregulate pyoverdine production at intermediate drug concentrations, but then down-scale investment levels at high drug concentrations (C). In contrast, flucytosine administration leads to an almost complete abolishment of pyoverdine production even at the lowest drug concentration. All data are expressed as average of growth yield, scaled relative to the drug-free treatment. Error bars denote standard errors of the mean across 6 (for flucytosine) and 18 (for gallium) replicates. Dose-response curves were fitted using a spline fit. Vertical lines indicate the drug concentrations used in the experimental evolution.</p></caption><graphic xlink:href="195974_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig></sec><sec id="s2d" hwp:id="sec-10"><title hwp:id="title-12">Quantification of resistance profiles</title><p hwp:id="p-17">To test whether populations evolved under antibacterial exposure restored growth and/or pyoverdine production, we exposed evolved lineages to the drug concentrations they experienced during experimental evolution in 5-fold replication. Following a standard protocol with incubation at 37° C, shaking at 160 rpm, for 24 hours [<xref rid="c44" ref-type="bibr" hwp:id="xref-ref-44-1" hwp:rel-id="ref-44">44</xref>], we compared the OD<sub>600</sub> and pyoverdine-associated fluorescence of evolved lineages relative to the ancestor wildtype grown under drug and no-drug treatment.</p><p hwp:id="p-18">To assess potential resistance profiles of individual clones, we streaked out aliquots of evolved lineages onto LB plates. After overnight incubation at 37°C, we randomly picked 200 clones (five colonies per lineage), and assessed their growth and pyoverdine production in 3-fold replication, as described above. Moreover, we performed an in-depth analysis for 20 (four per treatment) randomly picked single clones by quantifying their drug-inhibition curve, following the protocol described above.</p><p hwp:id="p-19">To test whether bacteria upregulated alternative iron-acquisition mechanisms, we quantified pyocyanin and protease production of selected clones. For pyocyanin production, overnight bacterial cultures were inoculated into 1 ml of LB (starting OD<sub>600</sub> = 10<sup>−6</sup>), and incubated at 37°C for 24 hours, shaken at 160 rpm. We measured pyocyanin in the cell-free supernatant through absorbance at 691 nm [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-8" hwp:rel-id="ref-19">19</xref>]. For protease production, overnight bacterial cultures were inoculated in human serum (starting OD<sub>600</sub> = 2.5 × 10<sup>−3</sup>), and incubated at 37°C for 24 hours, shaken at 160 rpm. Subsequently, we centrifuged cultures at 3700 rpm for 15 minutes to obtain protease-containing supernatants. To measure proteolytic activity, we adapted the protocol by [<xref rid="c45" ref-type="bibr" hwp:id="xref-ref-45-1" hwp:rel-id="ref-45">45</xref>]: 0.1 ml azocasein solution (30 mg/ml) were mixed with 0.3 ml 50 mM phosphate buffer (pH 7.5), and 0.1 ml culture supernatant. During incubation at 37°C (2 hours), proteases hydrolyze azocasein and release the azo-dye. Proteolytic reaction was stopped by adding 0.5 ml 20% trichloroacetic acid (TCA), samples centrifuged at 12000 rpm (10 min), and proteolytic activity measured through absorbance of the azo-dye at 366 nm.</p></sec><sec id="s2e" hwp:id="sec-11"><title hwp:id="title-13">Sequencing analysis</title><p hwp:id="p-20">We further isolated the genomic DNA of the selected 16 clones evolved under drug regimes and sequenced their genomes. We used the GenElute Bacterial Genomic DNA kit (Sigma Aldrich) for DNA isolation. DNA concentrations were assayed using the Quantifluor dsDNA sample kit (Promega). Samples were sent to the Functional Genomics Center Zurich for library preparation (Nextera XT) and sequencing. Sequencing was performed on the Illumina HiSeq 4000 platform with single-end 125 base pair reads. Adapter sequences were clipped using Trimmomatic v0.33 [<xref rid="c46" ref-type="bibr" hwp:id="xref-ref-46-1" hwp:rel-id="ref-46">46</xref>] and reads trimmed using Flexbar v2.5 [<xref rid="c47" ref-type="bibr" hwp:id="xref-ref-47-1" hwp:rel-id="ref-47">47</xref>]. We aligned the reads to the PAO1 reference genome using BWA v0.7.12 [<xref rid="c48" ref-type="bibr" hwp:id="xref-ref-48-1" hwp:rel-id="ref-48">48</xref>]. We applied GATK v3.5 [<xref rid="c49" ref-type="bibr" hwp:id="xref-ref-49-1" hwp:rel-id="ref-49">49</xref>] indel realignment, duplicate removal and HaplotypeCaller SNP/INDEL discovery according to the GATK Best Practices recommendations. This generated a variant call format (VCF) file, from which the following variants were discarded: (i) coverage &lt; 20 reads; (ii) Fisher Strand (FS) score &gt; 30.0, ensuring that there is no strand bias in the data; (iii) QD value &lt; 2.0 (confidence value that there is a true variation at a given site); and (iv) clustered variants (≥ 3 variants in 35nt window) as they likely present sequencing or alignment artifacts. This filtering process yielded a list of potential SNPs and small INDELs, which we annotated using snpEff 4.1g [<xref rid="c50" ref-type="bibr" hwp:id="xref-ref-50-1" hwp:rel-id="ref-50">50</xref>] and then screened manually, compared to the sequenced genome of our ancestor wildtype for relevant mutations in gene coding and intergenic regions (Supplementary Table S2).</p></sec><sec id="s2f" hwp:id="sec-12"><title hwp:id="title-14">Statistical analysis</title><p hwp:id="p-21">We used RStudio for statistical analysis (version 0.99.896, with R version 3.3.0). We analyzed growth curves and pyoverdine production profiles using the <italic toggle="yes">grofit</italic> package [<xref rid="c51" ref-type="bibr" hwp:id="xref-ref-51-1" hwp:rel-id="ref-51">51</xref>]. We fitted non-parametric model (Splines) curves to estimate growth yield and integral (area under the curve). For all analyses, we scaled growth yield and pyoverdine production relative to the untreated ancestral wildtype. We used general linear mixed effect models to compare whether growth parameters or pyoverdine profiles differ in evolved cultures treated with or without antibacterials. To test for differences between evolved lines and the ancestral wildtype, we used Welch‘s two-sample <italic toggle="yes">t</italic>-test. To compare the dose-response curve of evolved clones, we first fitted spline curves to the inhibition curves, then estimated the integrals of these fits, and compared the scaled fits relative to the ancestor wildtype using ANOVA (Analysis of variance). Protease and pyocyanin production of evolved clones and the ancestor wildtype were corrected for cell number (OD<sub>600</sub>) and analyzed using ANOVA.</p></sec></sec><sec id="s3" hwp:id="sec-13"><title hwp:id="title-15">Results</title><sec id="s3a" hwp:id="sec-14"><title hwp:id="title-16">Gallium and flucytosine curb growth and pyoverdine production in human serum</title><p hwp:id="p-22">To confirm that human serum is an iron-limited media, in which pyoverdine is important for growth, we compared the growth of our wildtype strain PAO1 to the pyoverdine-negative mutant PAO1 Δ<italic toggle="yes">pvdD</italic> in either pure human serum or human serum supplemented with transferrin (Supplementary Fig. S1). As expected for iron-limited media, we observed significantly reduced growth of the siderophore-deficient mutants compared to the wildtype (ANOVA: <italic toggle="yes">t</italic><sub>49</sub> = −8.13, <italic toggle="yes">p</italic> &lt; 0.0001) under both conditions.</p><p hwp:id="p-23">We then subjected PAO1 to a range of drug concentrations in human serum supplemented with transferrin. The resulting dose-response curves revealed that both drugs significantly affected growth and pyoverdine production, albeit following different patterns (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-2" hwp:rel-id="F1">Fig. 1</xref>). For gallium, growth reduction was moderate at low concentrations, and only became substantial at high concentrations (GaNO<sub>3</sub> ≥ 256 µM, <xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-3" hwp:rel-id="F1">Fig. 1A</xref>). Gallium treatment affected pyoverdine synthesis in a complex way (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-4" hwp:rel-id="F1">Fig. 1C</xref>), yet consistent with previous findings [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-9" hwp:rel-id="ref-19">19</xref>]: at intermediate gallium concentrations, pyoverdine is up-regulated to compensate for the gallium-induced pyoverdine inhibition, and down-regulated at higher concentrations, when pyoverdine-mediated signaling becomes impaired [<xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-4" hwp:rel-id="ref-23">23</xref>]. For flucytosine, already the lowest concentration caused a substantial growth reduction (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-5" hwp:rel-id="F1">Fig. 1B</xref>) and completely stalled pyoverdine production, with the reduction remaining fairly constant across the concentration gradient (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-6" hwp:rel-id="F1">Fig. 1D</xref>). We obtained similar response profiles when growing PAO1 in human serum without added transferrin (Supplementary Fig. S2), indicating that transferrin supplementation does not affect the drugs’ mode of actions. For all subsequent experiments, we used human serum with added transferrin to ensure strong iron limitation and to standardize conditions across experiments.</p></sec><sec id="s3b" hwp:id="sec-15"><title hwp:id="title-17">Do bacteria evolve population-level resistance to antivirulence treatments?</title><p hwp:id="p-24">We subjected PAO1 wildtype cultures to experimental evolution both in the absence and presence of gallium and flucytosine (two concentrations each). Eight independent lines per treatment were daily transferred to fresh human serum for a period of 20 days. Subsequently, we assessed whether evolved populations improved growth and/or pyoverdine production levels compared to the treated ancestral wildtype, which could provide first hints of resistance evolution.</p><p hwp:id="p-25">For growth (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Fig. 2A</xref>), we found that evolved lines grew significantly better under drug exposure than the ancestral wildtype (Welch’s t-tests, gallium low (50 µM): <italic toggle="yes">t</italic><sub>11.9</sub> = −4.96, <italic toggle="yes">p</italic> = 0.0003; gallium high (280 µM): <italic toggle="yes">t</italic><sub>13.3</sub> = −6.48, <italic toggle="yes">p</italic> &lt; 0.0001; flucytosine low (10 µg/ml): <italic toggle="yes">t</italic><sub>12.2</sub> = − 5.09, <italic toggle="yes">p</italic> = 0.0002; flucytosine high (140 µg/ml): <italic toggle="yes">t</italic><sub>7.5</sub> = −11.79, <italic toggle="yes">p</italic> &lt; 0.0001). Because growth increase could simply reflect adaptation to media components other than drugs, we also analyzed changes in growth performance of the lines evolved without drugs. It turned out that some of the untreated evolved lineages also showed improved growth compared to the ancestral wildtype, but the overall increase across lines was not significant (<italic toggle="yes">t</italic><sub>9.1</sub> = −1.61, <italic toggle="yes">p</italic> = 0.1424, <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Fig. 2A</xref>).</p><fig id="fig2" position="float" fig-type="figure" orientation="portrait" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3 xref-fig-2-4 xref-fig-2-5 xref-fig-2-6"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;195974v3/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2.</label><caption hwp:id="caption-2"><title hwp:id="title-18">Population level growth and pyoverdine production after evolution in human serum.</title><p hwp:id="p-26">PAO1 cultures were exposed to either no treatment, low (50 µM) or high (280 µM) gallium, low (10 µg/ml) or high (140 µg/ml) flucytosine concentrations during a 20-day experimental evolution experiment in eight-fold replication. Following evolution, we assessed growth and pyoverdine production of evolved populations (displayed on the x-axis) and compared their performance relative to the untreated (gray solid line, set to 1) and treated ancestral wildtype (black dashed line). (A) Compared to the treated ancestral wildtype, growth of evolved populations significantly increased under all treatment regimes. Growth also increased in some but not all of the non-treatment lines. (B) Pyoverdine production of evolved populations significantly increased relative to the untreated ancestral wildtype under all conditions, also in the no treatment lines. This indicates that increased pyoverdine production might be a general response to growth in human serum, which makes it difficult to disentangle resistance evolution from media adaptation. Error bars show the standard error of the mean across 5 independent replicates.</p></caption><graphic xlink:href="195974_fig2" position="float" orientation="portrait" hwp:id="graphic-2"/></fig><p hwp:id="p-27">For pyoverdine production, we observed no significant change for the lines evolved under low gallium concentration (comparison relative to the treated ancestor, Welch’s t-test: <italic toggle="yes">t</italic><sub>8.8</sub> = 0.94, <italic toggle="yes">p</italic> = 0.3719) (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Fig. 2B</xref>). Conversely, lines evolved under the other three drug regimes all showed significantly increased pyoverdine production (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-4" hwp:rel-id="F2">Fig. 2B</xref>) (gallium high: <italic toggle="yes">t</italic><sub>13.1</sub> = −3.69, <italic toggle="yes">p</italic> = 0.0026; flucytosine low: <italic toggle="yes">t</italic><sub>7.2</sub> = −7.64, <italic toggle="yes">p</italic> = 0.0001; flucytosine high: <italic toggle="yes">t</italic><sub>9.6</sub> = −54.65, <italic toggle="yes">p</italic> &lt; 0.0001). While the increase was moderate for the gallium high treatment, there was full restoration of pyoverdine production in both flucytosine treatments (no significant difference relative to the ancestral untreated wildtype, ANOVA, flucytosine low: <italic toggle="yes">t</italic><sub>88</sub> = −1.31, <italic toggle="yes">p</italic> = 0.1944; flucytosine high: <italic toggle="yes">t</italic><sub>88</sub> = 0.42, <italic toggle="yes">p</italic> = 0.6766). Although pyoverdine restoration might be taken as evidence for resistance evolution, analysis of the control lines shows that a significant increase in pyoverdine production also occurred in the absence of drugs (Welch’s t-test, <italic toggle="yes">t</italic><sub>9.1</sub>=−4.03, <italic toggle="yes">p</italic> = 0.0047, <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-5" hwp:rel-id="F2">Fig. 2B</xref>).</p></sec><sec id="s3c" hwp:id="sec-16"><title hwp:id="title-19">Screening for resistance profiles in evolved single clones</title><p hwp:id="p-28">While the population analyses above show that drug resistance and general media adaptation could both contribute to the evolved population growth and pyoverdine phenotypes, we decided to screen individual clones for in-depth analysis. In a first step, we isolated 200 random clones (i.e. 40 per treatment), and individually analyzed their growth and pyoverdine production. These analyses revealed high between-clone variation in growth and pyoverdine production (Supplementary Fig. S3 + S4), suggesting that most evolved populations were heterogeneous, consisting of multiple different genotypes. Interestingly, we observed that 25% of the evolved clones from the no-drug control lines lost the ability to produce pyoverdine (Supplementary Fig. S4). This observation matches the results from previous studies, showing that iron-limitation selects for non-producers that cheat on the pyoverdine produced by others [<xref rid="c52" ref-type="bibr" hwp:id="xref-ref-52-1" hwp:rel-id="ref-52">52</xref>, <xref rid="c53" ref-type="bibr" hwp:id="xref-ref-53-1" hwp:rel-id="ref-53">53</xref>]. Increased pyoverdine production at the population level (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-6" hwp:rel-id="F2">Fig. 2B</xref>) is then typically the result of wildtype cells over-compensating for the presence of non-producers [<xref rid="c54" ref-type="bibr" hwp:id="xref-ref-54-1" hwp:rel-id="ref-54">54</xref>, <xref rid="c55" ref-type="bibr" hwp:id="xref-ref-55-1" hwp:rel-id="ref-55">55</xref>]. Conversely, we did not detect non-producers in the four drug treatments, which suggests that selection pressures differ between the non-drug and the drug treatments.</p><p hwp:id="p-29">In a second step, we randomly picked 16 single clones (four per drug treatment) and tested whether these evolved clones differ in their drug dose response curve relative to the ancestral wildtype. We observed that three out of eight clones subjected to gallium (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Fig. 3A-3D</xref>) and all eight clones subjected to flucytosine showed a significantly altered dose response (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Fig. 3E</xref>-3H). Clones GL_2 and GL_3, evolved under low gallium, showed a significant increase in pyoverdine production under intermediate gallium concentrations (between 8 and 128 μM), which goes along with an improved growth performance for GL_2, but not GL_3. In contrast, clone GH_1, evolved under high gallium concentration, did not show an altered pyoverdine production response, but grew significantly better when exposed to gallium (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Fig. 3A</xref>-3D). For the eight clones evolved under the flucytosine regime, changes in the dose-response curves were both striking and uniform: growth and pyoverdine production were no longer affected by the drug (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-4" hwp:rel-id="F3">Fig. 3E</xref>-3H). Since these dose-response curves directly include a control for media adaptation (i.e. the no-drug treatment), our results indicate that all eight clones evolved complete resistance to flucytosine. For gallium, on the other hand, our data suggest that three out of the eight clones exhibited a phenotype that is compatible with at least partial resistance. To check whether these putative resistance profiles are unique to clones evolved under drug treatment, we further assessed the dose-response curves of 4 clones from the no-drug control lines (Supplementary Fig. S5). All these clones responded to both drugs in the same way as the susceptible ancestral wildtype, confirming that adaptation to human serum does not per se result in resistant phenotypes.</p><fig id="fig3" position="float" fig-type="figure" orientation="portrait" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3 xref-fig-3-4 xref-fig-3-5 xref-fig-3-6"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;195974v3/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3.</label><caption hwp:id="caption-3"><title hwp:id="title-20">Changes in dose-response curves for evolved single clones indicate resistance evolution.</title><p hwp:id="p-30">16 randomly picked clones, four per treatment, were exposed to a range of drug concentrations to test whether their dose-response altered during evolution compared to the ancestral wildtype (black circles and lines). (A and B) Growth dose-response curves under gallium treatment show that two evolved clones (GL2 and GH1) are significantly less inhibited than the ancestral wildtype. (C and D) Pyoverdine dose-response curves under gallium treatment show that two evolved clones (GL2 and GL3) make significantly more pyoverdine than the ancestral wildtype. (E and F) Growth dose-response curves under flucytosine treatment show that all evolved clones grow significantly better than the ancestral wildtype, and are in fact no longer affected by the drug. (G and H) Pyoverdine dose-response curves under flucytosine treatment show that all evolved clones produce significantly more pyoverdine than the ancestral wildtype, and are in fact no longer affected by the drug. Growth and pyoverdine production were measured after 24 h. For each clone, values are scaled relative to its performance in human serum without drugs (absolute values of pyoverdine and growth in the absence of treatment are reported in Supplementary Fig. S6). We used spline functions to fit dose-response curves, and used the integral (area under the curve) to quantify the overall dose response of each clone across the concentration gradient. Error bars denote standard errors of the mean across 6 replicates. Asterisks represent significance levels: * = <italic toggle="yes">p</italic> &lt; 0.05; *** = <italic toggle="yes">p</italic> &lt; 0.0001, based on linear model with <italic toggle="yes">df</italic> = 45.</p></caption><graphic xlink:href="195974_fig3" position="float" orientation="portrait" hwp:id="graphic-3"/></fig></sec><sec id="s3d" hwp:id="sec-17"><title hwp:id="title-21">Linking phenotypes to genotypes</title><p hwp:id="p-31">Our whole-genome sequencing of the 16 focal clones revealed a small number of SNPs and INDELs, which have emerged during experimental evolution (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">Table 1</xref>). All the clones evolved under flucytosine treatment had acquired mutations in the coding sequence of <italic toggle="yes">upp.</italic> There were four different types of mutations, including two different non-synonymous SNPs, a 15-bp deletion and a 1-bp insertion (Supplementary Table S3). The <italic toggle="yes">upp</italic> gene encodes for a uracil phosphoribosyl-transferase, an enzyme required for the intra-cellular activation of flucytosine [<xref rid="c56" ref-type="bibr" hwp:id="xref-ref-56-1" hwp:rel-id="ref-56">56</xref>, <xref rid="c57" ref-type="bibr" hwp:id="xref-ref-57-1" hwp:rel-id="ref-57">57</xref>].</p><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1 xref-table-wrap-1-2 xref-table-wrap-1-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;195974v3/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>Table 1.</label><caption hwp:id="caption-4"><title hwp:id="title-22">List of mutations in evolved single clones.</title></caption><graphic xlink:href="195974_tbl1" position="float" orientation="portrait" hwp:id="graphic-4"/></table-wrap><p hwp:id="p-32">For the clones evolved under gallium treatment, the mutational pattern was more heterogeneous (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-2" hwp:rel-id="T1">Table 1</xref>). No mutations were detected for three clones (GH_2, GH_3, GH_4). In contrast, the three clones with significantly altered dose responses had mutations potentially explaining their phenotypes: clone GH_1 featured a 3-nt deletion in <italic toggle="yes">mvaU</italic>, whereas the clones GL_2 and GL_3 were mutated in <italic toggle="yes">vfr</italic>. Both genes encode transcriptional regulators involved in the regulation of virulence factors, including proteases, pyocyanin and pyoverdine.</p><p hwp:id="p-33">In addition, several clones had mutations in <italic toggle="yes">dipA</italic> (dispersion-induced phosphodiesterase A; GL_1, GL_4, FH_4) and <italic toggle="yes">morA</italic> (motility regulator; GL_3, FH_2). The repeated yet unspecific appearance of these mutations could suggest that they represent non-drug-specific adaptations to human serum. Altogether, our sequencing analysis identified three potential targets explaining resistance evolution: the gene <italic toggle="yes">upp</italic> for flucytosine, and the genes encoding the transcriptional regulators <italic toggle="yes">vfr</italic> and <italic toggle="yes">mvaU</italic> for gallium.</p></sec><sec id="s3e" hwp:id="sec-18"><title hwp:id="title-23">Evolution of bypassing mechanisms for iron acquisition under gallium treatment</title><p hwp:id="p-34">It was proposed that bypassing mechanisms, which guarantee iron uptake in a siderophore-independent manner, could confer resistance to gallium [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-10" hwp:rel-id="ref-19">19</xref>]. One such by-passing mechanism could involve the up-regulation of pyocyanin, a molecule that can reduce ferric to ferrous iron outside the cell, thereby promoting direct iron uptake [<xref rid="c18" ref-type="bibr" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref>, <xref rid="c58" ref-type="bibr" hwp:id="xref-ref-58-1" hwp:rel-id="ref-58">58</xref>]. This scenario indeed seems to apply to the three clones mutated in <italic toggle="yes">mvaU</italic> or <italic toggle="yes">vfr</italic>, two regulators that control directly (<italic toggle="yes">mvaU</italic>) or indirectly (<italic toggle="yes">vfr</italic>) the expression of pyocyanin [<xref rid="c59" ref-type="bibr" hwp:id="xref-ref-59-1" hwp:rel-id="ref-59">59</xref>, <xref rid="c60" ref-type="bibr" hwp:id="xref-ref-60-1" hwp:rel-id="ref-60">60</xref>]. These clones displayed significantly increased pyocyanin production compared to the ancestral wildtype (<xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-1" hwp:rel-id="F4">Fig. 4A</xref>; ANOVA, GH_1: <italic toggle="yes">t</italic><sub>79</sub> = 9.64, <italic toggle="yes">p</italic> &lt; 0.0001; GL_2: <italic toggle="yes">t</italic><sub>99</sub> = 6.13, <italic toggle="yes">p</italic> &lt; 0.0001; GL_3: <italic toggle="yes">t</italic><sub>99</sub> = 14.8, <italic toggle="yes">p</italic> &lt; 0.0001).</p><fig id="fig4" position="float" fig-type="figure" orientation="portrait" hwp:id="F4" hwp:rev-id="xref-fig-4-1 xref-fig-4-2 xref-fig-4-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;195974v3/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Figure 4.</label><caption hwp:id="caption-5"><title hwp:id="title-24">Upregulation of pyocyanin or protease production as potential bypassing mechanisms for iron acquisition under gallium treatment.</title><p hwp:id="p-35">The eight sequenced clones evolved under gallium treatments (low: 50 µM, high: 280 µM) were screened for their change in the secretion of pyocyanin (A) and proteases (B) relative to the ancestral wildtype. Standard protocols were used for the phenotypic screens in drug free media (see Material and Methods for details). All values are corrected for cell number, and scaled relative to the ancestor wildtype (black line). We included the strains PAO1 Δ<italic toggle="yes">rhlR</italic> (deficient for pyocyanin production) and PAO1 Δ<italic toggle="yes">lasR</italic> (deficient for protease production) as negative controls in the respective assays (dashed lines). Error bars denote standard errors of the mean across 3 (for proteases) and 8 (for pyocyanin) replicates. Asterisks represent significance levels: * = <italic toggle="yes">p</italic> &lt; 0.05; *** = <italic toggle="yes">p</italic> &lt; 0.0001, based on ANOVA.</p></caption><graphic xlink:href="195974_fig4" position="float" orientation="portrait" hwp:id="graphic-5"/></fig><p hwp:id="p-36">A second by-passing mechanism could operate via increased protease production, which would allow iron acquisition from transferrin or heme through protease-induced hydrolysis [<xref rid="c29" ref-type="bibr" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">29</xref>, <xref rid="c61" ref-type="bibr" hwp:id="xref-ref-61-1" hwp:rel-id="ref-61">61</xref>]. We found no support for this hypothesis. In fact, six of the evolved clones exhibited reduced and not increased protease activity (<xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-2" hwp:rel-id="F4">Fig. 4B</xref>). Moreover, the two clones with significantly increased protease activity (ANOVA, GL_1: <italic toggle="yes">t</italic><sub>10</sub> = 13.22, <italic toggle="yes">p</italic> &lt; 0.0001; GL_4: <italic toggle="yes">t</italic><sub>10</sub> = 11.60, <italic toggle="yes">p</italic> &lt; 0.0001, <xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-3" hwp:rel-id="F4">Fig. 4B</xref>) did not show an altered drug dose-response curve.</p></sec><sec id="s3f" hwp:id="sec-19"><title hwp:id="title-25">Inactivation of Upp is responsible for resistance to flucytosine</title><p hwp:id="p-37">Next, we tested whether the mutations in <italic toggle="yes">upp</italic> are responsible for flucytosine resistance. The enzyme Upp (uracil phosphoribosyl-transferase) is essential for the activation of flucytosine within the cell. The natural function of Upp is to convert uracil to the nucleotide precursor UMP in the salvage pathway of pyrimidine (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Fig. 5A</xref>). However, <italic toggle="yes">P. aeruginosa</italic> can also produce UMP through the conversion of L-glutamine and L-aspartate [<xref rid="c62" ref-type="bibr" hwp:id="xref-ref-62-1" hwp:rel-id="ref-62">62</xref>] (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-2" hwp:rel-id="F5">Fig. 5A</xref>), suggesting that <italic toggle="yes">upp</italic> is not essential for pyrimidine metabolism. Mutations in this gene could thus prevent flucytosine activation, and confer drug resistance. To test this hypothesis, we compared the flucytosine dose-response curve of the wildtype strain to an isogenic (transposon) mutant (MPAO1Δ<italic toggle="yes">upp</italic>). Consistent with the patterns of the evolved clones (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-5" hwp:rel-id="F3">Fig. 3G</xref>), we found that MPAO1Δ<italic toggle="yes">upp</italic> was completely insensitive to flucytosine, with neither growth (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-3" hwp:rel-id="F5">Fig. 5B</xref>) nor pyoverdine production (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-4" hwp:rel-id="F5">Fig. 5C</xref>) being affected by the drug. These results indicate that <italic toggle="yes">upp</italic> inactivation is a simple and efficient mechanism to become flucytosine resistant.</p><fig id="fig5" position="float" fig-type="figure" orientation="portrait" hwp:id="F5" hwp:rev-id="xref-fig-5-1 xref-fig-5-2 xref-fig-5-3 xref-fig-5-4 xref-fig-5-5"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;195974v3/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>Figure 5.</label><caption hwp:id="caption-6"><title hwp:id="title-26">Upp is a non-essential enzyme, and mutations in its gene result in flucytosine resistance.</title><p hwp:id="p-38">(A) Flucytosine interferes with the pyrimidine metabolism in <italic toggle="yes">P. aeruginosa.</italic> The drug enters the cell through the transporter CodB (not shown), where it is first converted to fluorouracil by the cytosine deaminase CodA, and then to fluoro-UMP by the uracil phosphoribosyl-transferase Upp. Fluoro-UMP is a modified nucleotide precursor, the action of which results in RNA molecules with compromised functionality. Through an as yet unknown mechanism, fluoro-UMP also arrests pyoverdine synthesis in <italic toggle="yes">P. aeruginosa</italic>. Importantly, the nucleotide-precursor UMP can also be produced through an alternative <italic toggle="yes">de-novo</italic> pathway from the amino acids L-glutamine and L-aspartate, making Upp a non-essential enzyme in this bacterium. Experiments with the transposon mutant MPAO1 Δ<italic toggle="yes">upp</italic> (deficient for Upp production) indeed demonstrate that the lack of Upp no longer affects strain growth (B) and pyoverdine production (C). This demonstrates that the inactivation of <italic toggle="yes">upp</italic> is a simple and efficient way to evolve resistance to flucytosine. Experiments were carried out in human serum across a range of flucytosine concentrations. Growth and pyoverdine production of MPAO1 Δ<italic toggle="yes">upp</italic> (gray-dashed lines) and its corresponding wildtype MPAO1 (black-solid lines) were measured after 24 hours for each treatment separately in 6-fold replication. All values are scaled relative to the drug-free treatment. For statistical analysis, we compared the integrals of the dose-response curves between the mutant and the wildtype strain (Welch’s <italic toggle="yes">t</italic>-test, growth: <italic toggle="yes">t</italic><sub>4.3</sub> = −5.56, <italic toggle="yes">p</italic> = 0.0041; pyoverdine production: <italic toggle="yes">t</italic><sub>5.0</sub> = −48.80, <italic toggle="yes">p</italic> &lt; 0.0001).</p></caption><graphic xlink:href="195974_fig5" position="float" orientation="portrait" hwp:id="graphic-6"/></fig></sec></sec><sec id="s4" hwp:id="sec-20"><title hwp:id="title-27">Discussion</title><p hwp:id="p-39">New treatment approaches against the multi-drug resistant ESKAPE pathogens, to which <italic toggle="yes">P. aeruginosa</italic> belongs, are desperately needed [<xref rid="c8" ref-type="bibr" hwp:id="xref-ref-8-2" hwp:rel-id="ref-8">8</xref>, <xref rid="c63" ref-type="bibr" hwp:id="xref-ref-63-1" hwp:rel-id="ref-63">63</xref>, <xref rid="c64" ref-type="bibr" hwp:id="xref-ref-64-1" hwp:rel-id="ref-64">64</xref>]. In this context, treatments that disarm rather than kill bacteria have attracted particular interest, because such approaches have been proposed to be both effective in managing infections and sustainable in the sense that resistance should not easily evolve [<xref rid="c2" ref-type="bibr" hwp:id="xref-ref-2-3" hwp:rel-id="ref-2">2</xref>, <xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-2" hwp:rel-id="ref-5">5</xref>, <xref rid="c12" ref-type="bibr" hwp:id="xref-ref-12-3" hwp:rel-id="ref-12">12</xref>–<xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-5" hwp:rel-id="ref-15">15</xref>]. Promising approaches include the quenching of toxins [<xref rid="c65" ref-type="bibr" hwp:id="xref-ref-65-1" hwp:rel-id="ref-65">65</xref>, <xref rid="c66" ref-type="bibr" hwp:id="xref-ref-66-1" hwp:rel-id="ref-66">66</xref>], siderophores required for iron-scavenging [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-11" hwp:rel-id="ref-19">19</xref>, <xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-5" hwp:rel-id="ref-23">23</xref>, <xref rid="c24" ref-type="bibr" hwp:id="xref-ref-24-3" hwp:rel-id="ref-24">24</xref>, <xref rid="c37" ref-type="bibr" hwp:id="xref-ref-37-2" hwp:rel-id="ref-37">37</xref>, <xref rid="c67" ref-type="bibr" hwp:id="xref-ref-67-1" hwp:rel-id="ref-67">67</xref>], and quorum sensing molecules regulating virulence factor production [<xref rid="c3" ref-type="bibr" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref>]. In our study, we probed the evolutionary robustness argument by focusing on two repurposed drugs (gallium and flucytosine) targeting siderophore production of <italic toggle="yes">P. aeruginosa</italic>. Using a combination of replicated experimental evolution and phenotypic and genotypic analysis, we show that the often-recited argument of anti-virulence drugs being evolutionarily robust is not supported. Instead, we provide a nuanced view on the molecular mechanisms and selective forces that can lead to resistance. For flucytosine, for instance, we found repeated resistance evolution based on a mechanism that prevents drug activation inside the cell, which mitigates possible pleiotropic and deleterious effects caused by this drug. For gallium, meanwhile, two types of partially resistant mutants, based on siderophore bypassing mechanisms, arose. However, these mutants only sporadically emerged, indicating that their potential to selective spread in populations is compromised. Our work highlights that evolutionary robustness is a relative measure with specific treatments lying on different positions on a continuum. Thus, our task is not to argue about whether anti-virulence drugs are evolutionarily robust or not, but to assess the relative position of each novel treatment on this continuum.</p><p hwp:id="p-40">Our findings indicate that it is difficult to define anti-virulence treatments based on fitness effects [<xref rid="c2" ref-type="bibr" hwp:id="xref-ref-2-4" hwp:rel-id="ref-2">2</xref>, <xref rid="c6" ref-type="bibr" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>, <xref rid="c8" ref-type="bibr" hwp:id="xref-ref-8-3" hwp:rel-id="ref-8">8</xref>, <xref rid="c22" ref-type="bibr" hwp:id="xref-ref-22-2" hwp:rel-id="ref-22">22</xref>]. This is because fitness effects might vary in response to the ecological context of the media or the infection. For instance, prior work [<xref rid="c24" ref-type="bibr" hwp:id="xref-ref-24-4" hwp:rel-id="ref-24">24</xref>] showed that flucytosine does not affect bacterial growth in trypticase soy broth dialysate (TSBD), whereas we found significant fitness effects in human serum. Endorsing the fitness-based definition would mean that flucytosine could only be considered as an anti-virulence drug in very specific cases, i.e. in one media but not in another. This might cause confusion when we aim to bring these new treatment approaches to the clinic. While we agree that it would be ideal to find compounds that only curb virulence but not fitness, it seems that such cases are rare and context-dependent [<xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-3" hwp:rel-id="ref-5">5</xref>, <xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-6" hwp:rel-id="ref-15">15</xref>]. For all those reasons, we support the more general definition of antivirulence treatments as advocated in previous reviews [<xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-4" hwp:rel-id="ref-5">5</xref>, <xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-7" hwp:rel-id="ref-15">15</xref>]: drugs intended to target bacterial virulence factors.</p><p hwp:id="p-41">Important to note is that even when we use the more general definition of anti-virulence the chances are good that many of the new treatment approaches are evolutionary more robust than classical antibiotics. This is nicely illustrated in the case of gallium, where we found that partially resistant mutants only sporadically occurred. Given the mutation rate in <italic toggle="yes">P. aeruginosa</italic> and the number of generations that occurred in our experiment, the frequency of such mutants should be much higher if they had experienced a clear selective advantage (<xref rid="tbl2" ref-type="table" hwp:id="xref-table-wrap-2-1" hwp:rel-id="T2">Table 2</xref>). Our data thus highlight that it is important to distinguish between the appearance of resistant mutants and their evolutionary potential to spread through populations. At the mechanistic level, we isolated mutants with increased pyocyanin production, a potential mechanism to by-pass gallium-mediated pyoverdine quenching. Pyocyanin is a redox active molecule that can extracellularly reduce ferric to ferrous iron [<xref rid="c18" ref-type="bibr" hwp:id="xref-ref-18-2" hwp:rel-id="ref-18">18</xref>, <xref rid="c58" ref-type="bibr" hwp:id="xref-ref-58-2" hwp:rel-id="ref-58">58</xref>]. The upregulation of pyocyanin was associated with mutations in <italic toggle="yes">mvaU</italic>, encoding a positive regulator of pyocyanin production, and <italic toggle="yes">vfr</italic>, encoding a global virulence factor regulator [<xref rid="c10" ref-type="bibr" hwp:id="xref-ref-10-2" hwp:rel-id="ref-10">10</xref>]. Mutations in Vfr can activate PQS (Pseudomonas Quinolon Signal) synthesis, which is known to promote pyocyanin and pyoverdine synthesis [<xref rid="c60" ref-type="bibr" hwp:id="xref-ref-60-2" hwp:rel-id="ref-60">60</xref>, <xref rid="c68" ref-type="bibr" hwp:id="xref-ref-68-1" hwp:rel-id="ref-68">68</xref>]. At the evolutionary level, however, the selective advantage of these mutations seemed to be compromised because they occurred only in some of the sequenced clones (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-3" hwp:rel-id="T1">Table 1</xref>). One plausible explanation for their sporadic appearance is that pyocyanin could serve as a public good, reducing iron outside the cell, thereby generating benefits for other individuals in the vicinity, including the drug-susceptible wildtype cells. This scenario would support the argument that anti-virulence strategies should target collective traits, because this would prevent resistant mutants to fix in populations [<xref rid="c12" ref-type="bibr" hwp:id="xref-ref-12-4" hwp:rel-id="ref-12">12</xref>, <xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-2" hwp:rel-id="ref-14">14</xref>, <xref rid="c16" ref-type="bibr" hwp:id="xref-ref-16-3" hwp:rel-id="ref-16">16</xref>, <xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-12" hwp:rel-id="ref-19">19</xref>, <xref rid="c20" ref-type="bibr" hwp:id="xref-ref-20-2" hwp:rel-id="ref-20">20</xref>]. The relative success of these mutants is then determined by the viscosity of the environment, determining the shareability of secreted compounds [<xref rid="c69" ref-type="bibr" hwp:id="xref-ref-69-1" hwp:rel-id="ref-69">69</xref>], and the potential for negative-frequency dependent selection, where strain frequency settles at an intermediate ratio [<xref rid="c70" ref-type="bibr" hwp:id="xref-ref-70-1" hwp:rel-id="ref-70">70</xref>–<xref rid="c72" ref-type="bibr" hwp:id="xref-ref-72-1" hwp:rel-id="ref-72">72</xref>].</p><table-wrap id="tbl2" orientation="portrait" position="float" hwp:id="T2" hwp:rev-id="xref-table-wrap-2-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;195974v3/TBL2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T2</object-id><object-id pub-id-type="publisher-id">tbl2</object-id><label>Table 2</label><caption hwp:id="caption-7"><title hwp:id="title-28">Estimation of mutation supply during experimental evolution</title></caption><graphic xlink:href="195974_tbl2" position="float" orientation="portrait" hwp:id="graphic-7"/></table-wrap><p hwp:id="p-42">The pattern clearly differed for flucytosine, where we found pervasive resistance evolution. Although it is not exactly known how flucytosine inhibits pyoverdine synthesis, we argue that resistance evolution could mainly be caused by negative effects on other traits than pyoverdine synthesis. Flucytosine undergoes several enzymatic modifications within the cell, finally resulting in fluorinated ribonucleotides. While flucytosine was shown to inhibit pyoverdine synthesis [<xref rid="c24" ref-type="bibr" hwp:id="xref-ref-24-5" hwp:rel-id="ref-24">24</xref>], it likely also interferes with nucleotide synthesis, which might compromise RNA functionality more generally [<xref rid="c73" ref-type="bibr" hwp:id="xref-ref-73-1" hwp:rel-id="ref-73">73</xref>]. This sets the stage for selection to favor mutants with alleviated fitness costs under drug exposure. Our results suggest that cells achieved this through mutations in <italic toggle="yes">upp</italic>. The scheme depicted in <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-5" hwp:rel-id="F5">Fig. 5A</xref> shows that the essential pyrimidine nucleotide precursor UMP can be synthesized either through the salvage pathways reutilizing exogenous free bases and nucleosides, or via a <italic toggle="yes">de novo</italic> biosynthesis pathway using L-glutamine or L-aspartate. While the salvage pathway is typically preferred because it requires less energy, it generates the harmful fluoro-UMP under flucytosine treatment. Thus, the abolishment of the salvage pathway through mutations in <italic toggle="yes">upp</italic> and the switching to the <italic toggle="yes">de novo</italic> biosynthesis pathway provides a selective advantage under flucytosine exposure. The notion that off-target effects might compromise the evolutionary robustness of anti-virulence drugs, is also supported by the work of Maeda <italic toggle="yes">et al.</italic> [<xref rid="c17" ref-type="bibr" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref>]. They showed that resistance to the quorum-quenching compound C-30 (brominated furanone) evolves repeatedly via upregulation of a drug efflux pump. The spread of these mutants in their experiment can be explained by the fact that quorum quenching did not only inhibit virulence factor production, but also compromised the ability of cells to grow in adenosine medium, which requires a functional quorum sensing system [<xref rid="c74" ref-type="bibr" hwp:id="xref-ref-74-1" hwp:rel-id="ref-74">74</xref>].</p></sec><sec id="s5" hwp:id="sec-21"><title hwp:id="title-29">Conclusions and Implications</title><p hwp:id="p-43">Our work advances research on anti-virulence drugs on multiple fronts. First, it shows that resistant phenotypes are difficult to define, as they can involve the restoration of growth, the resumption of virulence factor production, and/or the activation of a bypassing mechanism. Detailed phenotypic and genotypic analyses, as those proposed in our study, are required to disentangle background adaptation from resistance evolution. Second, we show that anti-virulence approaches are neither completely evolution-proof nor does the notion “all roads lead to resistance” apply [<xref rid="c75" ref-type="bibr" hwp:id="xref-ref-75-1" hwp:rel-id="ref-75">75</xref>]. A detailed evolutionary analysis for each individual drug is required to assess its position on the continuum between the two extremes. Third, we advocate the application of more rigorous evolutionary approaches to quantify resistance evolution. While there are rigorous standards to describe the precise molecular mode of action of a novel antibacterial [<xref rid="c21" ref-type="bibr" hwp:id="xref-ref-21-2" hwp:rel-id="ref-21">21</xref>, <xref rid="c76" ref-type="bibr" hwp:id="xref-ref-76-1" hwp:rel-id="ref-76">76</xref>], there is much room for improvement for standards regarding the quantification and characterization of resistance evolution [<xref rid="c77" ref-type="bibr" hwp:id="xref-ref-77-1" hwp:rel-id="ref-77">77</xref>, <xref rid="c78" ref-type="bibr" hwp:id="xref-ref-78-1" hwp:rel-id="ref-78">78</xref>].</p></sec></body><back><sec id="s6" hwp:id="sec-22"><title hwp:id="title-30">Declarations of funding</title><p hwp:id="p-44">This work was funded by the Swiss National Science Foundation (R.K.) with grant no PP00P3_165835.</p></sec><sec id="s7" sec-type="COI-statement" hwp:id="sec-23"><title hwp:id="title-31">Conflict of Interest</title><p hwp:id="p-45">The authors declare no conflict of interest.</p></sec><ack hwp:id="ack-1"><title hwp:id="title-32">Acknowledgments</title><p hwp:id="p-46">We thank Adin Ross-Gillespie for advice, the Functional Genomics Center Zurich for technical support with the strain sequencing.</p></ack><sec id="s8" hwp:id="sec-24"><title hwp:id="title-33">Supplementary data</title><p hwp:id="p-47">Supplementary data are available at EMPH online. Whole-genome sequencing data have been deposited in the ArrayExpress database at EMBL-EBI (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://www.ebi.ac.uk/arrayexpress" ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/arrayexpress" hwp:id="ext-link-2">www.ebi.ac.uk/arrayexpress</ext-link>) under accession number E-MTAB-6110.</p></sec><ref-list hwp:id="ref-list-1"><title hwp:id="title-34">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Escaich S."><surname>Escaich</surname> <given-names>S.</given-names></string-name> <article-title hwp:id="article-title-2">Antivirulence as a new antibacterial approach for chemotherapy</article-title>. <source hwp:id="source-1">Curr Opin Chem Biol</source> <year>2008</year>;<volume>12</volume>:<fpage>400</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1 xref-ref-2-2 xref-ref-2-3 xref-ref-2-4"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Rasko DA"><surname>Rasko</surname> <given-names>DA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sperandio V."><surname>Sperandio</surname> <given-names>V.</given-names></string-name> <article-title hwp:id="article-title-3">Anti-virulence strategies to combat bacteria-mediated disease</article-title>. <source hwp:id="source-2">Nat Rev Drug Discov</source> <year>2010</year>;<volume>9</volume>:<fpage>117</fpage>–<lpage>28</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="LaSarre B"><surname>LaSarre</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Federle MJ"><surname>Federle</surname> <given-names>MJ</given-names></string-name>. <article-title hwp:id="article-title-4">Exploiting Quorum Sensing To Confuse Bacterial Pathogens</article-title>. <source hwp:id="source-3">Microbiol Mol Biol Rev</source> <year>2013</year>;<volume>77</volume>:<fpage>73</fpage>–<lpage>111</lpage>.</citation></ref><ref id="c4" hwp:id="ref-4"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Maura D"><surname>Maura</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ballok AE"><surname>Ballok</surname> <given-names>AE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rahme LG"><surname>Rahme</surname> <given-names>LG</given-names></string-name>. <article-title hwp:id="article-title-5">Considerations and caveats in anti-virulence drug development</article-title>. <source hwp:id="source-4">Curr Opin Microbiol</source> <year>2016</year>;<volume>33</volume>:<fpage>41</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1 xref-ref-5-2 xref-ref-5-3 xref-ref-5-4"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.5" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Vale PF"><surname>Vale</surname> <given-names>PF</given-names></string-name>, <string-name name-style="western" hwp:sortable="McNally L"><surname>McNally</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Doeschl-Wilson A"><surname>Doeschl-Wilson</surname> <given-names>A</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-6">Beyond killing</article-title>. <source hwp:id="source-5">Evol Med Public Heal</source> <year>2016</year>;2016:<fpage>148</fpage>–<lpage>57</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Johnson BK"><surname>Johnson</surname> <given-names>BK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Abramovitch RB"><surname>Abramovitch</surname> <given-names>RB</given-names></string-name>. <article-title hwp:id="article-title-7">Small Molecules That Sabotage Bacterial Virulence</article-title>. <source hwp:id="source-6">Trends Pharmacol Sci</source> <year>2017</year>;<volume>38</volume>:<fpage>339</fpage>–<lpage>62</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.7" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Rampioni G"><surname>Rampioni</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Visca P"><surname>Visca</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Leoni L"><surname>Leoni</surname> <given-names>L</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-8">Drug repurposing for antivirulence therapy against opportunistic bacterial pathogens</article-title>. <source hwp:id="source-7">Emerg Top Life Sci</source> <year>2017</year>:ETLS20160018.</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1 xref-ref-8-2 xref-ref-8-3"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Dickey SW"><surname>Dickey</surname> <given-names>SW</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cheung GYC"><surname>Cheung</surname> <given-names>GYC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Otto M."><surname>Otto</surname> <given-names>M.</given-names></string-name> <article-title hwp:id="article-title-9">Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance</article-title>. <source hwp:id="source-8">Nat Rev Drug Discov</source> <year>2017</year>;<volume>16</volume>:<fpage>1</fpage>–<lpage>15</lpage>.</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><label>9.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Rahme LG"><surname>Rahme</surname> <given-names>LG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stevens EJ"><surname>Stevens</surname> <given-names>EJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wolfort SF"><surname>Wolfort</surname> <given-names>SF</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-10">Common virulence factors for bacterial pathogenicity in plants and animals</article-title>. <source hwp:id="source-9">Science (80-)</source> <year>1995</year>;<volume>268</volume>:<fpage>1899</fpage>–<lpage>902</lpage>.</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1 xref-ref-10-2"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Balasubramanian D"><surname>Balasubramanian</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schneper L"><surname>Schneper</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kumari H"><surname>Kumari</surname> <given-names>H</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-11">A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence</article-title>. <source hwp:id="source-10">Nucleic Acids Res</source> <year>2013</year>;<volume>41</volume>:<fpage>1</fpage>–<lpage>20</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Wu HJ"><surname>Wu</surname> <given-names>HJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang AHJ"><surname>Wang</surname> <given-names>AHJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jennings MP"><surname>Jennings</surname> <given-names>MP</given-names></string-name>. <article-title hwp:id="article-title-12">Discovery of virulence factors of pathogenic bacteria</article-title>. <source hwp:id="source-11">Curr Opin Chem Biol</source> <year>2008</year>;<volume>12</volume>:<fpage>93</fpage>–<lpage>101</lpage>.</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1 xref-ref-12-2 xref-ref-12-3 xref-ref-12-4"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="André JB"><surname>André</surname> <given-names>JB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Godelle B."><surname>Godelle</surname> <given-names>B.</given-names></string-name> <article-title hwp:id="article-title-13">Multicellular organization in bacteria as a target for drug therapy</article-title>. <source hwp:id="source-12">Ecol Lett</source> <year>2005</year>;<volume>8</volume>:<fpage>800</fpage>–<lpage>10</lpage>.</citation></ref><ref id="c13" hwp:id="ref-13"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Baron C."><surname>Baron</surname> <given-names>C.</given-names></string-name> <article-title hwp:id="article-title-14">Antivirulence drugs to target bacterial secretion systems</article-title>. <source hwp:id="source-13">Curr Opin Microbiol</source> <year>2010</year>;<volume>13</volume>:<fpage>100</fpage>–<lpage>5</lpage>.</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1 xref-ref-14-2"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Pepper JW"><surname>Pepper</surname> <given-names>JW</given-names></string-name>. <article-title hwp:id="article-title-15">Drugs that target pathogen public goods are robust against evolved drug resistance</article-title>. <source hwp:id="source-14">Evol Appl</source> <year>2012</year>;<volume>5</volume>:<fpage>757</fpage>–<lpage>61</lpage>.</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1 xref-ref-15-2 xref-ref-15-3 xref-ref-15-4 xref-ref-15-5 xref-ref-15-6 xref-ref-15-7"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Allen RC"><surname>Allen</surname> <given-names>RC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Popat R"><surname>Popat</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Diggle SP"><surname>Diggle</surname> <given-names>SP</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-16">Targeting virulence: can we make evolution-proof drugs?</article-title> <source hwp:id="source-15">Nat Rev Microbiol</source> <year>2014</year>;<volume>12</volume>:<fpage>300</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1 xref-ref-16-2 xref-ref-16-3"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Mellbye B"><surname>Mellbye</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schuster M."><surname>Schuster</surname> <given-names>M.</given-names></string-name> <article-title hwp:id="article-title-17">The sociomicrobiology of antivirulence drug resistance: a proof of concept</article-title>. <source hwp:id="source-16">MBio</source> <year>2011</year>;<volume>2</volume>:<fpage>e00131</fpage>–<lpage>11</lpage>.</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Maeda T"><surname>Maeda</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="García-Contreras R"><surname>García-Contreras</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pu M"><surname>Pu</surname> <given-names>M</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-18">Quorum quenching quandary: resistance to antivirulence compounds</article-title>. <source hwp:id="source-17">ISME J</source> <year>2012</year>;<volume>6</volume>:<fpage>493</fpage>–<lpage>501</lpage>.</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1 xref-ref-18-2"><label>18.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="García-Contreras R"><surname>García-Contreras</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lira-Silva E"><surname>Lira-Silva</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jasso-Chávez R"><surname>Jasso-Chávez</surname> <given-names>R</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-19">Isolation and characterization of gallium resistant Pseudomonas aeruginosa mutants</article-title>. <source hwp:id="source-18">Int J Med Microbiol</source> <year>2013</year>;<volume>303</volume>:<fpage>574</fpage>–<lpage>82</lpage>.</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1 xref-ref-19-2 xref-ref-19-3 xref-ref-19-4 xref-ref-19-5 xref-ref-19-6 xref-ref-19-7 xref-ref-19-8 xref-ref-19-9 xref-ref-19-10 xref-ref-19-11 xref-ref-19-12 xref-ref-19-13"><label>19.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Ross-Gillespie A"><surname>Ross-Gillespie</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Weigert M"><surname>Weigert</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brown SP"><surname>Brown</surname> <given-names>SP</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-20">Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment</article-title>. <source hwp:id="source-19">Evol Med Public Heal</source> <year>2014</year>;<volume>2014</volume>:<fpage>18</fpage>–<lpage>29</lpage>.</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1 xref-ref-20-2"><label>20.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Gerdt JP"><surname>Gerdt</surname> <given-names>JP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Blackwell HE"><surname>Blackwell</surname> <given-names>HE</given-names></string-name>. <article-title hwp:id="article-title-21">Competition Studies Confirm Two Major Barriers That Can Preclude the Spread of Resistance to Quorum-Sensing Inhibitors in Bacteria</article-title>. <source hwp:id="source-20">ACS Chem Biol</source> <year>2014</year>;<volume>9</volume>:<fpage>2291</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1 xref-ref-21-2"><label>21.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Sully EK"><surname>Sully</surname> <given-names>EK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Malachowa N"><surname>Malachowa</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Elmore BO"><surname>Elmore</surname> <given-names>BO</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-22">Selective Chemical Inhibition of agr Quorum Sensing in Staphylococcus aureus Promotes Host Defense with Minimal Impact on Resistance</article-title>. <source hwp:id="source-21">PLoS Pathog</source> <year>2014</year>;<volume>10</volume>:<fpage>e1004174</fpage>.</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1 xref-ref-22-2"><label>22.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Clatworthy AE"><surname>Clatworthy</surname> <given-names>AE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pierson E"><surname>Pierson</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hung DT"><surname>Hung</surname> <given-names>DT</given-names></string-name>. <article-title hwp:id="article-title-23">Targeting virulence: a new paradigm for antimicrobial therapy</article-title>. <source hwp:id="source-22">Nat Chem Biol</source> <year>2007</year>;<volume>3</volume>:<fpage>541</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1 xref-ref-23-2 xref-ref-23-3 xref-ref-23-4 xref-ref-23-5"><label>23.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Kaneko Y"><surname>Kaneko</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Thoendel M"><surname>Thoendel</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Olakanmi O"><surname>Olakanmi</surname> <given-names>O</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-24">The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity</article-title>. <source hwp:id="source-23">J Clin Invest</source> <year>2007</year>;<volume>117</volume>:<fpage>877</fpage>–<lpage>88</lpage>.</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1 xref-ref-24-2 xref-ref-24-3 xref-ref-24-4 xref-ref-24-5"><label>24.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Imperi F"><surname>Imperi</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Massai F"><surname>Massai</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Facchini M"><surname>Facchini</surname> <given-names>M</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-25">Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity</article-title>. <source hwp:id="source-24">Proc Natl Acad Sci U S A</source> <year>2013</year>;<volume>110</volume>:<fpage>7458</fpage>–<lpage>63</lpage>.</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1"><label>25.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Meyer JM"><surname>Meyer</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Neely A"><surname>Neely</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stintzi A"><surname>Stintzi</surname> <given-names>A</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-26">Pyoverdin is essential for virulence of Pseudomonas aeruginosa</article-title>. <source hwp:id="source-25">Infect Immun</source> <year>1996</year>;<volume>64</volume>:<fpage>518</fpage>–<lpage>23</lpage>.</citation></ref><ref id="c26" hwp:id="ref-26"><label>26.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Takase H"><surname>Takase</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nitanai H"><surname>Nitanai</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hoshino K"><surname>Hoshino</surname> <given-names>K</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-27">Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice</article-title>. <source hwp:id="source-26">Infect Immun</source> <year>2000</year>;<volume>68</volume>:<fpage>1834</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c27" hwp:id="ref-27"><label>27.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Harrison F"><surname>Harrison</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Browning LE"><surname>Browning</surname> <given-names>LE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vos M"><surname>Vos</surname> <given-names>M</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-28">Cooperation and virulence in acute Pseudomonas aeruginosa infections</article-title>. <source hwp:id="source-27">BMC Biol</source> <year>2006</year>;<volume>4</volume>:<fpage>21</fpage>.</citation></ref><ref id="c28" hwp:id="ref-28"><label>28.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Cornelis P"><surname>Cornelis</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dingemans J."><surname>Dingemans</surname> <given-names>J.</given-names></string-name> <article-title hwp:id="article-title-29">Pseudomonas aeruginosa adapts its iron uptake strategies in function of the type of infections</article-title>. <source hwp:id="source-28">Front Cell Infect Microbiol</source> <year>2013</year>;<volume>3</volume>:<fpage>1</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1"><label>29.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Bonchi C"><surname>Bonchi</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Imperi F"><surname>Imperi</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Minandri F"><surname>Minandri</surname> <given-names>F</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-30">Repurposing of gallium-based drugs for antibacterial therapy</article-title>. <source hwp:id="source-29">BioFactors</source> <year>2014</year>;<volume>40</volume>:<fpage>303</fpage>–<lpage>12</lpage>.</citation></ref><ref id="c30" hwp:id="ref-30"><label>30.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Granato ET"><surname>Granato</surname> <given-names>ET</given-names></string-name>, <string-name name-style="western" hwp:sortable="Harrison F"><surname>Harrison</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kümmerli R"><surname>Kümmerli</surname> <given-names>R</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-31">Do Bacterial “Virulence Factors” Always Increase Virulence? A Meta-Analysis of Pyoverdine Production in Pseudomonas aeruginosa As a Test Case</article-title>. <source hwp:id="source-30">Front Microbiol</source> <year>2016</year>;<volume>7</volume>:<fpage>1</fpage>–<lpage>13</lpage>.</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1 xref-ref-31-2"><label>31.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Weigert M"><surname>Weigert</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ross-Gillespie A"><surname>Ross-Gillespie</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Leinweber A"><surname>Leinweber</surname> <given-names>A</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-32">Manipulating virulence factor availability can have complex consequences for infections</article-title>. <source hwp:id="source-31">Evol Appl</source> <year>2017</year>;<volume>10</volume>:<fpage>91</fpage>–<lpage>101</lpage>.</citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1"><label>32.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Valenti P"><surname>Valenti</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Berlutti F"><surname>Berlutti</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Conte MP"><surname>Conte</surname> <given-names>MP</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-33">Lactoferrin Functions: Current Status and Perspectives</article-title>. <source hwp:id="source-32">J Clin Gastroenterol</source> <year>2004</year>;<volume>38</volume>:<fpage>S127</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1"><label>33.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Smith DJ"><surname>Smith</surname> <given-names>DJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lamont IL"><surname>Lamont</surname> <given-names>IL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anderson GJ"><surname>Anderson</surname> <given-names>GJ</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-34">Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis</article-title>. <source hwp:id="source-33">Eur Respir J</source> <year>2013</year>;<volume>42</volume>:<fpage>1723</fpage>–<lpage>36</lpage>.</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1"><label>34.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.34" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Visca P"><surname>Visca</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Imperi F"><surname>Imperi</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lamont IL"><surname>Lamont</surname> <given-names>IL</given-names></string-name>. <article-title hwp:id="article-title-35">Pyoverdine siderophores: from biogenesis to biosignificance</article-title>. <source hwp:id="source-34">Trends Microbiol</source> <year>2007</year>;<volume>15</volume>:<fpage>22</fpage>–<lpage>30</lpage>.</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1"><label>35.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.35" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Bonchi C"><surname>Bonchi</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Frangipani E"><surname>Frangipani</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Imperi F"><surname>Imperi</surname> <given-names>F</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-36">Pyoverdine and proteases affect the response of Pseudomonas aeruginosa to gallium in human serum</article-title>. <source hwp:id="source-35">Antimicrob Agents Chemother</source> <year>2015</year>;<volume>59</volume>:<fpage>5641</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1"><label>36.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.36" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="Banin E"><surname>Banin</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lozinski A"><surname>Lozinski</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brady KM"><surname>Brady</surname> <given-names>KM</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-37">The potential of desferrioxamine-gallium as an antiPseudomonas therapeutic agent</article-title>. <source hwp:id="source-36">Proc Natl Acad Sci U S A</source> <year>2008</year>;<volume>105</volume>:<fpage>16761</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1 xref-ref-37-2"><label>37.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="DeLeon K"><surname>DeLeon</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Balldin F"><surname>Balldin</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Watters C"><surname>Watters</surname> <given-names>C</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-38">Gallium Maltolate Treatment Eradicates Pseudomonas aeruginosa Infection in Thermally Injured Mice</article-title>. <source hwp:id="source-37">Antimicrob Agents Chemother</source> <year>2009</year>;<volume>53</volume>:<fpage>1331</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1"><label>38.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Chitambar CR"><surname>Chitambar</surname> <given-names>CR</given-names></string-name>. <article-title hwp:id="article-title-39">Gallium-containing anticancer compounds</article-title>. <source hwp:id="source-38">Future Med Chem</source> <year>2012</year>;<volume>4</volume>:<fpage>1257</fpage>–<lpage>72</lpage>.</citation></ref><ref id="c39" hwp:id="ref-39" hwp:rev-id="xref-ref-39-1"><label>39.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.39" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-39"><string-name name-style="western" hwp:sortable="Hijazi S"><surname>Hijazi</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Visca P"><surname>Visca</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Frangipani E."><surname>Frangipani</surname> <given-names>E.</given-names></string-name> <article-title hwp:id="article-title-40">Gallium-Protoporphyrin IX Inhibits Pseudomonas aeruginosa Growth by Targeting Cytochromes</article-title>. <source hwp:id="source-39">Front Cell Infect Microbiol</source> <year>2017</year>;<volume>7</volume>:<fpage>1</fpage>–<lpage>15</lpage>.</citation></ref><ref id="c40" hwp:id="ref-40" hwp:rev-id="xref-ref-40-1"><label>40.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.40" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-40"><string-name name-style="western" hwp:sortable="Waldorf AR"><surname>Waldorf</surname> <given-names>AR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Polak A."><surname>Polak</surname> <given-names>A.</given-names></string-name> <article-title hwp:id="article-title-41">Mechanisms of action of 5-fluorocytosine</article-title>. <source hwp:id="source-40">Antimicrob Agents Chemother</source> <year>1983</year>;<volume>23</volume>:<fpage>79</fpage>–<lpage>85</lpage>.</citation></ref><ref id="c41" hwp:id="ref-41" hwp:rev-id="xref-ref-41-1"><label>41.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.41" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-41"><string-name name-style="western" hwp:sortable="Hughes D"><surname>Hughes</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Andersson DI"><surname>Andersson</surname> <given-names>DI</given-names></string-name>. <article-title hwp:id="article-title-42">Evolutionary Trajectories to Antibiotic Resistance</article-title>. <source hwp:id="source-41">Annu Rev Microbiol</source> <year>2017</year>;<volume>71</volume>:<fpage>579</fpage>–<lpage>96</lpage>.</citation></ref><ref id="c42" hwp:id="ref-42" hwp:rev-id="xref-ref-42-1"><label>42.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.42" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-42"><string-name name-style="western" hwp:sortable="Griffin AS"><surname>Griffin</surname> <given-names>AS</given-names></string-name>, <string-name name-style="western" hwp:sortable="West SA"><surname>West</surname> <given-names>SA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Buckling A."><surname>Buckling</surname> <given-names>A.</given-names></string-name> <article-title hwp:id="article-title-43">Cooperation and competition in pathogenic bacteria</article-title>. <source hwp:id="source-42">Nature</source> <year>2004</year>;<volume>430</volume>:<fpage>1024</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c43" hwp:id="ref-43" hwp:rev-id="xref-ref-43-1"><label>43.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.43" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-43"><string-name name-style="western" hwp:sortable="Inglis RF"><surname>Inglis</surname> <given-names>RF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Biernaskie JM"><surname>Biernaskie</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gardner A"><surname>Gardner</surname> <given-names>A</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-44">Presence of a loner strain maintains cooperation and diversity in well-mixed bacterial communities</article-title>. <source hwp:id="source-43">Proc R Soc B Biol Sci</source> <year>2016</year>;<volume>283</volume>, doi:<pub-id pub-id-type="doi">10.1098/rspb.2015.2682</pub-id>.</citation></ref><ref id="c44" hwp:id="ref-44" hwp:rev-id="xref-ref-44-1"><label>44.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.44" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-44"><string-name name-style="western" hwp:sortable="Kümmerli R"><surname>Kümmerli</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jiricny N"><surname>Jiricny</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Clarke LS"><surname>Clarke</surname> <given-names>LS</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-45">Phenotypic plasticity of a cooperative behaviour in bacteria</article-title>. <source hwp:id="source-44">J Evol Biol</source> <year>2009</year>;<volume>22</volume>:<fpage>589</fpage>–<lpage>98</lpage>.</citation></ref><ref id="c45" hwp:id="ref-45" hwp:rev-id="xref-ref-45-1"><label>45.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.45" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-45"><string-name name-style="western" hwp:sortable="Chessa JP"><surname>Chessa</surname> <given-names>JP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Petrescu I"><surname>Petrescu</surname> <given-names>I</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bentahir M"><surname>Bentahir</surname> <given-names>M</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-46">Purification, physico-chemical characterization and sequence of a heat labile alkaline metalloprotease isolated from a psychrophilic Pseudomonas species</article-title>. <source hwp:id="source-45">Biochim Biophys Acta - Protein Struct Mol Enzymol</source> <year>2000</year>;<volume>1479</volume>:<fpage>265</fpage>–<lpage>74</lpage>.</citation></ref><ref id="c46" hwp:id="ref-46" hwp:rev-id="xref-ref-46-1"><label>46.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.46" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-46"><string-name name-style="western" hwp:sortable="Bolger AM"><surname>Bolger</surname> <given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lohse M"><surname>Lohse</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Usadel B."><surname>Usadel</surname> <given-names>B.</given-names></string-name> <article-title hwp:id="article-title-47">Trimmomatic: a flexible trimmer for Illumina sequence data</article-title>. <source hwp:id="source-46">Bioinformatics</source> <year>2014</year>;<volume>30</volume>:<fpage>2114</fpage>–<lpage>20</lpage>.</citation></ref><ref id="c47" hwp:id="ref-47" hwp:rev-id="xref-ref-47-1"><label>47.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.47" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-47"><string-name name-style="western" hwp:sortable="Dodt M"><surname>Dodt</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Roehr J"><surname>Roehr</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ahmed R"><surname>Ahmed</surname> <given-names>R</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-48">FLEXBAR—Flexible Barcode and Adapter Processing for Next-Generation Sequencing Platforms</article-title>. <source hwp:id="source-47">Biology (Basel)</source> <year>2012</year>;<volume>1</volume>:<fpage>895</fpage>–<lpage>905</lpage>.</citation></ref><ref id="c48" hwp:id="ref-48" hwp:rev-id="xref-ref-48-1"><label>48.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.48" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-48"><string-name name-style="western" hwp:sortable="Li H"><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Durbin R."><surname>Durbin</surname> <given-names>R.</given-names></string-name> <article-title hwp:id="article-title-49">Fast and accurate short read alignment with Burrows–Wheeler transform</article-title>. <source hwp:id="source-48">Bioinformatics</source> <year>2009</year>;<volume>25</volume>:<fpage>1754</fpage>–<lpage>60</lpage>.</citation></ref><ref id="c49" hwp:id="ref-49" hwp:rev-id="xref-ref-49-1"><label>49.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.49" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-49"><string-name name-style="western" hwp:sortable="McKenna A"><surname>McKenna</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hanna M"><surname>Hanna</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Banks E"><surname>Banks</surname> <given-names>E</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-50">The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>. <source hwp:id="source-49">Genome Res</source> <year>2010</year>;<volume>20</volume>:<fpage>1297</fpage>–<lpage>303</lpage>.</citation></ref><ref id="c50" hwp:id="ref-50" hwp:rev-id="xref-ref-50-1"><label>50.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.50" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-50"><string-name name-style="western" hwp:sortable="Cingolani P"><surname>Cingolani</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Platts A"><surname>Platts</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang LL"><surname>Wang</surname> <given-names>LL</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-51">A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff</article-title>. <source hwp:id="source-50">Fly (Austin)</source> <year>2012</year>;<volume>6</volume>:<fpage>80</fpage>–<lpage>92</lpage>.</citation></ref><ref id="c51" hwp:id="ref-51" hwp:rev-id="xref-ref-51-1"><label>51.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.51" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-51"><string-name name-style="western" hwp:sortable="Kahm M"><surname>Kahm</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hasenbrink G"><surname>Hasenbrink</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ludwig J."><surname>Ludwig</surname> <given-names>J.</given-names></string-name> <article-title hwp:id="article-title-52">grofit: Fitting Biological Growth Curves with R</article-title>. <source hwp:id="source-51">J Stat Softw</source> <year>2010</year>;<volume>33</volume>:<fpage>1</fpage>–<lpage>21</lpage>.</citation></ref><ref id="c52" hwp:id="ref-52" hwp:rev-id="xref-ref-52-1"><label>52.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.52" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-52"><string-name name-style="western" hwp:sortable="Harrison F"><surname>Harrison</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Paul J"><surname>Paul</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Massey RC"><surname>Massey</surname> <given-names>RC</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-53">Interspecific competition and siderophore-mediated cooperation in Pseudomonas aeruginosa</article-title>. <source hwp:id="source-52">ISME J</source> <year>2008</year>;<volume>2</volume>:<fpage>49</fpage>–<lpage>55</lpage>.</citation></ref><ref id="c53" hwp:id="ref-53" hwp:rev-id="xref-ref-53-1"><label>53.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.53" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-53"><string-name name-style="western" hwp:sortable="Dumas Z"><surname>Dumas</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kümmerli R."><surname>Kümmerli</surname> <given-names>R.</given-names></string-name> <article-title hwp:id="article-title-54">Cost of cooperation rules selection for cheats in bacterial metapopulations</article-title>. <source hwp:id="source-53">J Evol Biol</source> <year>2012</year>;<volume>25</volume>:<fpage>473</fpage>–<lpage>84</lpage>.</citation></ref><ref id="c54" hwp:id="ref-54" hwp:rev-id="xref-ref-54-1"><label>54.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.54" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-54"><string-name name-style="western" hwp:sortable="Harrison F."><surname>Harrison</surname> <given-names>F.</given-names></string-name> <article-title hwp:id="article-title-55">Dynamic social behaviour in a bacterium: Pseudomonas aeruginosa partially compensates for siderophore loss to cheats</article-title>. <source hwp:id="source-54">J Evol Biol</source> <year>2013</year>;<volume>26</volume>:<fpage>1370</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c55" hwp:id="ref-55" hwp:rev-id="xref-ref-55-1"><label>55.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.55" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-55"><string-name name-style="western" hwp:sortable="Ross-Gillespie A"><surname>Ross-Gillespie</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dumas Z"><surname>Dumas</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kümmerli R."><surname>Kümmerli</surname> <given-names>R.</given-names></string-name> <article-title hwp:id="article-title-56">Evolutionary dynamics of interlinked public goods traits: An experimental study of siderophore production in Pseudomonas aeruginosa</article-title>. <source hwp:id="source-55">J Evol Biol</source> <year>2015</year>;<volume>28</volume>:<fpage>29</fpage>–<lpage>39</lpage>.</citation></ref><ref id="c56" hwp:id="ref-56" hwp:rev-id="xref-ref-56-1"><label>56.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.56" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-56"><string-name name-style="western" hwp:sortable="Beck DA"><surname>Beck</surname> <given-names>DA</given-names></string-name>, <string-name name-style="western" hwp:sortable="O’Donovan GA"><surname>O’Donovan</surname> <given-names>GA</given-names></string-name>. <article-title hwp:id="article-title-57">Pathways of pyrimidine salvage in Pseudomonas and former Pseudomonas: Detection of recycling enzymes using high-performance liquid chromatography</article-title>. <source hwp:id="source-56">Curr Microbiol</source> <year>2008</year>;<volume>56</volume>:<fpage>162</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c57" hwp:id="ref-57" hwp:rev-id="xref-ref-57-1"><label>57.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.57" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-57"><string-name name-style="western" hwp:sortable="Edlind TD"><surname>Edlind</surname> <given-names>TD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Katiyar SK"><surname>Katiyar</surname> <given-names>SK</given-names></string-name>. <article-title hwp:id="article-title-58">Mutational Analysis of Flucytosine Resistance in Candida glabrata</article-title>. <source hwp:id="source-57">Antimicrob Agents Chemother</source> <year>2010</year>;<volume>54</volume>:<fpage>4733</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c58" hwp:id="ref-58" hwp:rev-id="xref-ref-58-1 xref-ref-58-2"><label>58.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.58" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-58"><string-name name-style="western" hwp:sortable="Cox CD"><surname>Cox</surname> <given-names>CD</given-names></string-name>. <article-title hwp:id="article-title-59">Role of pyocyanin in the acquisition of iron from transferrin</article-title>. <source hwp:id="source-58">Infect Immun</source> <year>1986</year>;<volume>52</volume>:<fpage>263</fpage>–<lpage>70</lpage>.</citation></ref><ref id="c59" hwp:id="ref-59" hwp:rev-id="xref-ref-59-1"><label>59.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.59" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-59"><string-name name-style="western" hwp:sortable="Li C"><surname>Li</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wally H"><surname>Wally</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Miller SJ"><surname>Miller</surname> <given-names>SJ</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-60">The multifaceted proteins MvaT and MvaU, members of the H-NS family, control arginine metabolism, pyocyanin synthesis, and prophage activation in Pseudomonas aeruginosa PAO1</article-title>. <source hwp:id="source-59">J Bacteriol</source> <year>2009</year>;<volume>191</volume>:<fpage>6211</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c60" hwp:id="ref-60" hwp:rev-id="xref-ref-60-1 xref-ref-60-2"><label>60.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.60" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-60"><string-name name-style="western" hwp:sortable="Diggle SP"><surname>Diggle</surname> <given-names>SP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Matthijs S"><surname>Matthijs</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wright VJ"><surname>Wright</surname> <given-names>VJ</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-61">The Pseudomonas aeruginosa 4-Quinolone Signal Molecules HHQ and PQS Play Multifunctional Roles in Quorum Sensing and Iron Entrapment</article-title>. <source hwp:id="source-60">Chem Biol</source> <year>2007</year>;<volume>14</volume>:<fpage>87</fpage>–<lpage>96</lpage>.</citation></ref><ref id="c61" hwp:id="ref-61" hwp:rev-id="xref-ref-61-1"><label>61.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.61" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-61"><string-name name-style="western" hwp:sortable="Doring G"><surname>Doring</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pfestorf M"><surname>Pfestorf</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Botzenhart K"><surname>Botzenhart</surname> <given-names>K</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-62">Impact of Proteases on Iron Uptake of Pseudomonas aeruginosa Pyoverdin from Transferrin and Lactoferrin</article-title>. <source hwp:id="source-61">Infect Immun</source> <year>1988</year>;<volume>56</volume>:<fpage>291</fpage>–<lpage>3</lpage>.</citation></ref><ref id="c62" hwp:id="ref-62" hwp:rev-id="xref-ref-62-1"><label>62.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.62" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-62"><string-name name-style="western" hwp:sortable="Isaac JH"><surname>Isaac</surname> <given-names>JH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Holloway BW"><surname>Holloway</surname> <given-names>BW</given-names></string-name>. <article-title hwp:id="article-title-63">Control of pyrimidine biosynthesis in Pseudomonas aeruginosa</article-title>. <source hwp:id="source-62">J Bacteriol</source> <year>1968</year>;<volume>96</volume>:<fpage>1732</fpage>–<lpage>41</lpage>.</citation></ref><ref id="c63" hwp:id="ref-63" hwp:rev-id="xref-ref-63-1"><label>63.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.63" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-63"><string-name name-style="western" hwp:sortable="Pendleton JN"><surname>Pendleton</surname> <given-names>JN</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gorman SP"><surname>Gorman</surname> <given-names>SP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gilmore BF"><surname>Gilmore</surname> <given-names>BF</given-names></string-name>. <article-title hwp:id="article-title-64">Clinical relevance of the ESKAPE pathogens</article-title>. <source hwp:id="source-63">Expert Rev Anti Infect Ther</source> <year>2013</year>;<volume>11</volume>:<fpage>297</fpage>–<lpage>308</lpage>.</citation></ref><ref id="c64" hwp:id="ref-64" hwp:rev-id="xref-ref-64-1"><label>64.</label><citation publication-type="other" citation-type="journal" ref:id="195974v3.64" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-64"><string-name name-style="western" hwp:sortable="Brown D."><surname>Brown</surname> <given-names>D.</given-names></string-name> <article-title hwp:id="article-title-65">Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat Rev Drug Discov</article-title> <year>2015</year>;<volume>14</volume>:<fpage>821</fpage>–<lpage>32</lpage>.</citation></ref><ref id="c65" hwp:id="ref-65" hwp:rev-id="xref-ref-65-1"><label>65.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.65" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-65"><string-name name-style="western" hwp:sortable="Lu C"><surname>Lu</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Maurer CK"><surname>Maurer</surname> <given-names>CK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kirsch B"><surname>Kirsch</surname> <given-names>B</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-66">Overcoming the Unexpected Functional Inversion of a PqsR Antagonist in Pseudomonas aeruginosaLJ: An In Vivo Potent Antivirulence Agent Targeting pqs Quorum Sensing</article-title>. <source hwp:id="source-64">Angew Chemie Int Ed</source> <year>2014</year>;<volume>53</volume>:<fpage>1109</fpage>–<lpage>12</lpage>.</citation></ref><ref id="c66" hwp:id="ref-66" hwp:rev-id="xref-ref-66-1"><label>66.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.66" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-66"><string-name name-style="western" hwp:sortable="Henry BD"><surname>Henry</surname> <given-names>BD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Neill DR"><surname>Neill</surname> <given-names>DR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Becker KA"><surname>Becker</surname> <given-names>KA</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-67">Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice</article-title>. <source hwp:id="source-65">Nat Biotechnol</source> <year>2015</year>;<volume>33</volume>:<fpage>81</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c67" hwp:id="ref-67" hwp:rev-id="xref-ref-67-1"><label>67.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.67" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-67"><string-name name-style="western" hwp:sortable="Kelson AB"><surname>Kelson</surname> <given-names>AB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Carnevali M"><surname>Carnevali</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Truong-Le V."><surname>Truong-Le</surname> <given-names>V.</given-names></string-name> <article-title hwp:id="article-title-68">Gallium-based anti-infectives: targeting microbial iron-uptake mechanisms</article-title>. <source hwp:id="source-66">Curr Opin Pharmacol</source> <year>2013</year>;<volume>13</volume>:<fpage>707</fpage>–<lpage>16</lpage>.</citation></ref><ref id="c68" hwp:id="ref-68" hwp:rev-id="xref-ref-68-1"><label>68.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.68" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-68"><string-name name-style="western" hwp:sortable="Lin J"><surname>Lin</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhang W"><surname>Zhang</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cheng J"><surname>Cheng</surname> <given-names>J</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-69">A Pseudomonas T6SS effector recruits PQS-containing outer membrane vesicles for iron acquisition</article-title>. <source hwp:id="source-67">Nat Commun</source> <year>2017</year>;<volume>8</volume>:<fpage>14888</fpage>.</citation></ref><ref id="c69" hwp:id="ref-69" hwp:rev-id="xref-ref-69-1"><label>69.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.69" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-69"><string-name name-style="western" hwp:sortable="Weigert M"><surname>Weigert</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kümmerli R."><surname>Kümmerli</surname> <given-names>R.</given-names></string-name> <article-title hwp:id="article-title-70">The physical boundaries of public goods cooperation between surface-attached bacterial cells</article-title>. <source hwp:id="source-68">Proc R Soc B Biol Sci</source> <year>2017</year>;<volume>284</volume>.</citation></ref><ref id="c70" hwp:id="ref-70" hwp:rev-id="xref-ref-70-1"><label>70.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.70" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-70"><string-name name-style="western" hwp:sortable="Ross-Gillespie A"><surname>Ross-Gillespie</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gardner A"><surname>Gardner</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="West SA"><surname>West</surname> <given-names>SA</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-71">Frequency dependence and cooperation: theory and a test with bacteria</article-title>. <source hwp:id="source-69">Am Nat</source> <year>2007</year>;<volume>170</volume>:<fpage>331</fpage>–<lpage>42</lpage>.</citation></ref><ref id="c71" hwp:id="ref-71"><label>71.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.71" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-71"><string-name name-style="western" hwp:sortable="Raymond B"><surname>Raymond</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="West SA"><surname>West</surname> <given-names>SA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Griffin AS"><surname>Griffin</surname> <given-names>AS</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-72">The dynamics of cooperative bacterial virulence in the field</article-title>. <source hwp:id="source-70">Science (80-)</source> <year>2012</year>;<volume>337</volume>:<fpage>85</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c72" hwp:id="ref-72" hwp:rev-id="xref-ref-72-1"><label>72.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.72" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-72"><string-name name-style="western" hwp:sortable="Yurtsev EA"><surname>Yurtsev</surname> <given-names>EA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chao HX"><surname>Chao</surname> <given-names>HX</given-names></string-name>, <string-name name-style="western" hwp:sortable="Datta MS"><surname>Datta</surname> <given-names>MS</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-73">Bacterial cheating drives the population dynamics of cooperative antibiotic resistance plasmids</article-title>. <source hwp:id="source-71">Mol Syst Biol</source> <year>2013</year>;<volume>9</volume>:<fpage>683</fpage>.</citation></ref><ref id="c73" hwp:id="ref-73" hwp:rev-id="xref-ref-73-1"><label>73.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.73" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-73"><string-name name-style="western" hwp:sortable="Harbers E"><surname>Harbers</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chaudhuri NK"><surname>Chaudhuri</surname> <given-names>NK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Heidelberger C."><surname>Heidelberger</surname> <given-names>C.</given-names></string-name> <article-title hwp:id="article-title-74">Studies on fluorinated pyrimidines. VIII. Further biochemical and metabolic investigations</article-title>. <source hwp:id="source-72">J Biol Chem</source> <year>1959</year>;<volume>234</volume>:<fpage>1255</fpage>–<lpage>62</lpage>.</citation></ref><ref id="c74" hwp:id="ref-74" hwp:rev-id="xref-ref-74-1"><label>74.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.74" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-74"><string-name name-style="western" hwp:sortable="Dandekar AA"><surname>Dandekar</surname> <given-names>AA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chugani S"><surname>Chugani</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Greenberg EP"><surname>Greenberg</surname> <given-names>EP</given-names></string-name>. <article-title hwp:id="article-title-75">Bacterial Quorum Sensing and Metabolic Incentives to Cooperate</article-title>. <source hwp:id="source-73">Science</source> <year>2012</year>;<volume>338</volume>:<fpage>264</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c75" hwp:id="ref-75" hwp:rev-id="xref-ref-75-1"><label>75.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.75" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-75"><string-name name-style="western" hwp:sortable="Breidenstein EBM"><surname>Breidenstein</surname> <given-names>EBM</given-names></string-name>, <string-name name-style="western" hwp:sortable="de la Fuente-Núñez C"><surname>de la Fuente-Núñez</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hancock REW"><surname>Hancock</surname> <given-names>REW</given-names></string-name>. <article-title hwp:id="article-title-76">Pseudomonas aeruginosa: all roads lead to resistance</article-title>. <source hwp:id="source-74">Trends Microbiol</source> <year>2011</year>;<volume>19</volume>:<fpage>419</fpage>–<lpage>26</lpage>.</citation></ref><ref id="c76" hwp:id="ref-76" hwp:rev-id="xref-ref-76-1"><label>76.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.76" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-76"><string-name name-style="western" hwp:sortable="Ling LL"><surname>Ling</surname> <given-names>LL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schneider T"><surname>Schneider</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Peoples AJ"><surname>Peoples</surname> <given-names>AJ</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-77">A new antibiotic kills pathogens without detectable resistance</article-title>. <source hwp:id="source-75">Nature</source> <year>2015</year>;<volume>517</volume>:<fpage>455</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c77" hwp:id="ref-77" hwp:rev-id="xref-ref-77-1"><label>77.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.77" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-77"><string-name name-style="western" hwp:sortable="Perron GG"><surname>Perron</surname> <given-names>GG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zasloff M"><surname>Zasloff</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bell G."><surname>Bell</surname> <given-names>G.</given-names></string-name> <article-title hwp:id="article-title-78">Experimental evolution of resistance to an antimicrobial peptide</article-title>. <source hwp:id="source-76">Proc R Soc B Biol Sci</source> <year>2006</year>;<volume>273</volume>:<fpage>251 LP</fpage>–<lpage>256</lpage>.</citation></ref><ref id="c78" hwp:id="ref-78" hwp:rev-id="xref-ref-78-1"><label>78.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.78" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-78"><string-name name-style="western" hwp:sortable="Hochberg ME"><surname>Hochberg</surname> <given-names>ME</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jansen G."><surname>Jansen</surname> <given-names>G.</given-names></string-name> <article-title hwp:id="article-title-79">Bacteria: Assessing resistance to new antibiotics</article-title>. <source hwp:id="source-77">Nature</source> <year>2015</year>;<volume>519</volume>:<fpage>158</fpage>.</citation></ref><ref id="c79" hwp:id="ref-79"><label>79.</label><citation publication-type="journal" citation-type="journal" ref:id="195974v3.79" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-79"><string-name name-style="western" hwp:sortable="McElroy KE"><surname>McElroy</surname> <given-names>KE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hui JGK"><surname>Hui</surname> <given-names>JGK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Woo JKK"><surname>Woo</surname> <given-names>JKK</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-80">Strain-specific parallel evolution drives short-term diversification during Pseudomonas aeruginosa biofilm formation</article-title>. <source hwp:id="source-78">Proc Natl Acad Sci</source> <year>2014</year>;<volume>111</volume>: <fpage>E1419</fpage>–<lpage>E1427</lpage>.</citation></ref></ref-list><sec id="s9" sec-type="supplementary-material" hwp:id="sec-25"><title hwp:id="title-35">Supporting information captions</title><p hwp:id="p-48"><bold>Supplementary Figure S1. Human Serum is an iron limited media.</bold> To show that pyoverdine production is beneficial in human serum, we compared growth of <italic toggle="yes">P. aeruginosa</italic> PAO1 wildtype and the siderophore-deficient mutant PAO1 Δ<italic toggle="yes">pvdD</italic>, in pure human serum or human serum supplemented with the strong iron chelator human apo-transferrin (100 μg/ml) and its co-factor NaHCO<sub>3</sub> (20 mM). When adding only 50 mM HEPES to buffer the medium at physiological pH (first panel) we observed that growth of the siderophore mutant was significantly reduced compared to the wildtype (Welch’s t-test, <italic toggle="yes">t</italic><sub>9</sub>= 7.31, <italic toggle="yes">p</italic> &lt; 0.0001), confirming that human serum is an iron-limited media. When we increased iron limitation (second panel), we found that overall growth decreased compared to pure human serum (ANOVA, growth in human serum + transferrin: <italic toggle="yes">t</italic><sub>21</sub>= −22.35, <italic toggle="yes">p</italic> &lt; 0.0001), but that the wildtype PAO1 still grew significantly better compared to the siderophore mutant. (Welch’s t-test, <italic toggle="yes">t</italic><sub>10</sub>= 3.30, <italic toggle="yes">p</italic> &lt; 0.0086), confirming that the siderophore pyoverdine is important for iron scavenging in human serum. All growth data are scaled relative to the wildtype growth in human serum supplemented with HEPES 50 mM. Error bars denote standard errors of the mean across 6 replicates.</p><p hwp:id="p-49"><bold>Supplementary Figure S2. Gallium and flucytosine affect growth and pyoverdine production of <italic toggle="yes">P. aeruginosa</italic> in plain human serum, not supplemented with additional transferrin.</bold> To test the possibility that the two drugs affect growth and pyoverdine differently in human serum with and without additional transferrin, we performed dose-response curves in plain human serum, without adding the iron-chelator. We found that both anti-virulence drugs reduce growth of bacterial cultures (A, B) and pyoverdine production (C, D) in a dose-dependent manner, similarly to the reduction observed in human serum with transferrin (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-7" hwp:rel-id="F1">Fig. 1</xref>). As PAO1 has higher growth potential in plain serum (Supplementary Fig. S1A), the inhibitory effect of the two drugs at high concentrations was more pronounced than in serum with transferrin. Error bars denote standard errors of the mean across 6 replicates. Dose-response curves were fitted using a spline fit.</p><p hwp:id="p-50"><bold>Supplementary Figure S3. Growth and pyoverdine production profiles of evolved single clones under treatment regimes.</bold> We were interested in examining the variation in growth and pyoverdine production profiles among evolved clones. For that purpose, we streaked out all evolved cultures on LB agar, and picked 5 random clones per evolved population. Overall, we isolated 160 clones, 40 clones per treatment. Single clones were tested under the treatment regime experienced during experimental evolution, and growth and pyoverdine production were measured after 24 hours. Panels show growth and pyoverdine production of evolved clones relative to the untreated wildtype (grey line) under gallium (A, C) and flucytosine treatment (B, D). We found heterogeneous growth and pyoverdine patterns under all treatment regimes, suggesting diversification in evolving populations. Data points show means across three independent replicates. Dashed lines depict the mean growth or the mean pyoverdine production of the ancestral strain under treatment. Labeled single clones marked in red refer to the clones used for in-depth analysis and sequencing.</p><p hwp:id="p-51"><bold>Supplementary Figure S4. Pyoverdine non-producer strains evolved in human serum with transferrin in the no-drug control treatment.</bold> The strong iron limitation in human serum with transferrin could alone exert selective pressure during the experimental evolution, independently from the drug. This could affect the ability of the evolved clones to produce siderophore in response to the iron-limitation. To investigate these effects and control for general adaptation to low iron conditions, we isolated 40 clones from each treatment (gallium low, gallium high, flucytosine low; flucytosine high; no-drug control) and screened their ability to produce pyoverdine in human serum with transferrin. We observed that in the populations evolved without drug, pyoverdine-negative clones evolved at a frequency of approx. 25%. On the contrary, all clones from the drug treatments still produced pyoverdine. Each data point represents a single measurement per evolved clone. The black line denotes the average wildtype production level in the same assay and the grey area refers to the wildtype mean ± standard error of 20 replicates.</p><p hwp:id="p-52"><bold>Supplementary Figure S5: Evolved clones from the no-drug control treatment remain sensitive to both gallium and flucytosine.</bold> We were interested in determining whether media adaptation could per se lead to reduced susceptibility to gallium and flucytosine. To test this, we picked 4 random clones from the no-drug evolved population and subjected them to a range of drug concentration, for both gallium and flucytosine, to measure if they still respond to the drug. Growth dose-response curves under treatment showed that all evolved clones were equally or more sensitive to both gallium (A-B) and flucytosine (E-F), compared to the ancestor PAO1. Similarly, pyoverdine dose-response curves showed that all clones were still affected by gallium (C-D). Under flucytosine, three clones, were slightly less sensitive to flucytosine compared to the ancestor (G-H), although they can still considered sensitive to the antimicrobial if compared to the resistant clones isolated from the flucytosine high or low treatment (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-6" hwp:rel-id="F3">Figure 3</xref> G-H). Growth and pyoverdine production were measured after 24 h. For each clone, values are scaled relative to its performance in human serum without drugs. We used spline functions to fit dose-response curves, and used the integral (area under the curve) to quantify the overall dose response of each clone across the concentration gradient. Error bars denote standard errors of the mean across 6 replicates. Asterisks represent significance levels: * = p &lt; 0.05; *** = p &lt; 0.0001, based on linear model with df = 30.</p><p hwp:id="p-53"><bold>Supplementary Figure S6. Growth and pyoverdine production of evolved single clones in human serum with no treatment.</bold> We quantified the growth (A) and pyoverdine production (B) of the 16 evolved single clones we used for in-depth analysis and whole-genome sequencing. Specifically, we grew the clones for 24 hours in human serum and compared their performance to the ancestor wildtype in absence of the treatments. This allowed us to test for media adaptation. (A) We observed that some of the clones from both treatments showed significantly improved growth compared to the ancestral wildtype. This was the case for clones GL1 (<italic toggle="yes">t</italic><sub>43</sub> = 2.04, <italic toggle="yes">p</italic> = 0.0475), GL_4 (<italic toggle="yes">t</italic><sub>43</sub> = 2.04, <italic toggle="yes">p</italic> = 0.0475), GH_1 (<italic toggle="yes">t</italic><sub>43</sub> = 3.13, <italic toggle="yes">p</italic> = 0.0125), FL_1 (<italic toggle="yes">t</italic><sub>43</sub> = 5.88, <italic toggle="yes">p</italic> &lt; 0.0001) and all clones evolved under high flucytosine (FH_1: <italic toggle="yes">t</italic><sub>43</sub> = 3.09, <italic toggle="yes">p</italic> = 0.0054; FH_2:, <italic toggle="yes">t</italic><sub>43</sub> = 3.03, <italic toggle="yes">p</italic> = 0.0054; FH_3: <italic toggle="yes">t</italic><sub>43</sub> = 4.38, <italic toggle="yes">p</italic> = 0.0002; FH_4, <italic toggle="yes">t</italic><sub>43</sub> = 2.82, <italic toggle="yes">p</italic> = 0.0071). Interestingly, two of the clones evolved under gallium low treatment showed reduced growth compared to PAO1 (GL_2: <italic toggle="yes">t</italic><sub>43</sub> = −3.35, <italic toggle="yes">p</italic> = 0.0033; GL_3: <italic toggle="yes">t</italic><sub>43</sub> = −3.36, <italic toggle="yes">p</italic> = 0.0033). (B) Regarding per capita pyoverdine production (pyoverdine fluorescence divided by growth), we found that two clones showed increased levels of pyoverdine production under gallium treatment (GL_1: <italic toggle="yes">t</italic><sub>43</sub> = 2.79, <italic toggle="yes">p</italic> = 0.0200; GL_4: <italic toggle="yes">t</italic><sub>43</sub> = 2.69, <italic toggle="yes">p</italic> = 0.0200), and three clones of the flucytosine high treatment did so too (FH_1: t<sub>43</sub> = 2.43, p = 0.0356; FH_2: <italic toggle="yes">t</italic><sub>43</sub> = 2.29, <italic toggle="yes">p</italic> = 0.0356; for FH_4: <italic toggle="yes">t</italic><sub>43</sub> = 2.35, <italic toggle="yes">p</italic> = 0.0356). In contrast, there were also a number clones with significantly reduced pyoverdine production compared to PAO1 (GH_1: <italic toggle="yes">t</italic><sub>43</sub>= −3.14, <italic toggle="yes">p</italic> = 0.0045; GH_3: <italic toggle="yes">t</italic><sub>43</sub>= −3.10, <italic toggle="yes">p</italic> = 0.0045; GH_4: <italic toggle="yes">t</italic><sub>43</sub>= −3.46, <italic toggle="yes">p</italic> = 0.0045; FL_4: <italic toggle="yes">t</italic><sub>43</sub>= −2.02, <italic toggle="yes">p</italic>=0.0488). All data are scaled relative to the ancestor wildtype. Error bars denote standard error of the mean across 6 replicates. Asterisks represent significance codes (* = p&lt;0.05; ** = p&lt;0.001, *** = p&lt;0.0001 based on ANOVA, corrected for multiple pairwise comparison with the false discovery rate method).</p><p hwp:id="p-54"><bold>Supplementary Figure S7. Alteration of the fluorescent properties of pyoverdine when bound to gallium.</bold> The fluorescent signal of pyoverdine becomes inflated when gallium binds to it [<xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-13" hwp:rel-id="ref-19">19</xref>]. To take this signal bias into account, we quantified the bias in fluorescence signal as a function of gallium concentration. Specifically, we supplemented iron-limited human serum with 200 μM of purified pyoverdine across a range of gallium concentrations (8 to 512 μM, as used for the main experiments). We found that the signal bias can be explained by a 3 parameters-logistic function. We used this function to correct for signal bias in all our analyses.</p><p hwp:id="p-55"><bold>Supplementary Table S1. List of control strains used in this study.</bold></p><p hwp:id="p-56"><bold>Supplementary Table S2. Differences to the PAO1 reference genome shared among all sequenced evolved clones and the ancestor wildtype.</bold></p><p hwp:id="p-57"><bold>Supplementary Table S3. Effects of mutation on the Upp protein sequence of evolved single clones</bold></p></sec></back></article>
